<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Surgical management of resectable esophageal and esophagogastric junction cancers
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Surgical management of resectable esophageal and esophagogastric junction cancers
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Surgical management of resectable esophageal and esophagogastric junction cancers
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Scott Swanson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth K Tanabe, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Brian E Louie, MD, MHA, MPH, FRCSC, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Wenliang Chen, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 17, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Esophageal cancer presents as localized disease, defined as adenocarcinoma or squamous cell carcinoma confined to the esophagus, in approximately 22 percent of all cases [
         <a href="#rid1">
          1
         </a>
         ]. Regional disease, which includes spread to regional lymph nodes, accounts for another 30 percent of patients with esophageal cancer. The goal of surgical management is curative, and a surgical resection is the traditional mainstay of multidisciplinary therapy for patients with localized disease [
         <a href="#rid2">
          2-5
         </a>
         ]. The clinical spectrum of esophageal cancer has changed over the last few decades, with an increase in incidence of adenocarcinoma and a decrease of squamous cell carcinoma [
         <a href="#rid6">
          6-11
         </a>
         ]. Surgical management in the United States is independent of histology.
        </p>
        <p>
         The selection criteria and surgical management of patients with esophageal cancer are discussed in this topic. Neoadjuvant and adjuvant chemotherapy and radiation therapy, and management of patients with unresectable esophageal cancer, are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/2478.html" rel="external">
          "Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2472.html" rel="external">
          "Management of locally advanced, unresectable and inoperable esophageal cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H32960253">
         <span class="h1">
          ANATOMY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The esophagus, which is approximately 25 to 30 cm in length, is located in the posterior mediastinum and extends from the level of the 7
         <sup>
          th
         </sup>
         cervical vertebra to the 11
         <sup>
          th
         </sup>
         thoracic vertebra  (
         <a class="graphic graphic_figure graphicRef61563" href="/z/d/graphic/61563.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef70566" href="/z/d/graphic/70566.html" rel="external">
          figure 2
         </a>
         and
         <a class="graphic graphic_figure graphicRef55061" href="/z/d/graphic/55061.html" rel="external">
          figure 3
         </a>
         ). It is divided into four anatomic areas including the cervical, thoracic, and lower thoracic/esophagogastric junction and the abdominal esophagus  (
         <a class="graphic graphic_figure graphicRef67045" href="/z/d/graphic/67045.html" rel="external">
          figure 4
         </a>
         and
         <a class="graphic graphic_figure graphicRef54654" href="/z/d/graphic/54654.html" rel="external">
          figure 5
         </a>
         and
         <a class="graphic graphic_figure graphicRef111260" href="/z/d/graphic/111260.html" rel="external">
          figure 6
         </a>
         ). The esophagus is composed of the mucosa, submucosa, muscularis externa, and adventitia  (
         <a class="graphic graphic_diagnosticimage graphicRef73301" href="/z/d/graphic/73301.html" rel="external">
          image 1
         </a>
         ). There are three critical anatomic points of narrowing: the cricopharyngeus muscle, the bronchoaortic constriction, and the esophagogastric junction, which are also the most common sites of iatrogenic and mechanical perforation  (
         <a class="graphic graphic_figure graphicRef54206" href="/z/d/graphic/54206.html" rel="external">
          figure 7
         </a>
         and
         <a class="graphic graphic_figure graphicRef75732" href="/z/d/graphic/75732.html" rel="external">
          figure 8
         </a>
         ) [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         The arterial supply includes the inferior thyroid artery (cervical esophagus), bronchial arteries, and the aorta (thoracic esophagus) and branches of the left gastric artery and inferior phrenic artery (abdominal esophagus)  (
         <a class="graphic graphic_figure graphicRef83473" href="/z/d/graphic/83473.html" rel="external">
          figure 9
         </a>
         ). The venous drainage is through the inferior thyroid vein (cervical esophagus); the azygous vein, the hemiazygous vein, or the bronchial veins (thoracic esophagus); and the coronary vein (abdominal esophagus)  (
         <a class="graphic graphic_figure graphicRef83472" href="/z/d/graphic/83472.html" rel="external">
          figure 10
         </a>
         ).
        </p>
        <p>
         The esophagus has a rich network of lymphatic channels in the submucosa that can facilitate the longitudinal spread of neoplastic cells along the esophageal wall. Lymphatic drainage is to cervical nodes, tracheobronchial and mediastinal nodes, and gastric and celiac nodes  (
         <a class="graphic graphic_figure graphicRef83471" href="/z/d/graphic/83471.html" rel="external">
          figure 11
         </a>
         ). An important point is that the regional lymph nodes for all locations in the esophagus, including the cervical esophagus and esophagogastric junction, extend from the periesophageal cervical nodes to celiac nodes  (
         <a class="graphic graphic_figure graphicRef111319" href="/z/d/graphic/111319.html" rel="external">
          figure 12
         </a>
         ) [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7375097">
         <span class="h1">
          HISTOLOGY OF ESOPHAGEAL CANCER
         </span>
         <span class="headingEndMark">
          —
         </span>
         The two most common histologic types of esophageal cancer are squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma arises from the cells that line the esophagus; adenocarcinoma arises from glandular cells that are most commonly located at the junction of the esophagus and stomach but can vary based on the length of Barrett's esophagus.
        </p>
        <p class="headingAnchor" id="H32960261">
         <span class="h1">
          TNM STAGING
         </span>
         <span class="headingEndMark">
          —
         </span>
         The tumor, node, metastasis (TNM) staging system of the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) for esophageal cancer is used universally. The current AJCC TNM staging system (eighth edition, 2017) recognizes the biologic heterogeneity of the disease and provides separate stage groupings for adenocarcinoma and squamous cell carcinoma  (
         <a class="graphic graphic_table graphicRef111221" href="/z/d/graphic/111221.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2502.html" rel="external">
          "Clinical manifestations, diagnosis, and staging of esophageal cancer", section on 'TNM staging criteria'
         </a>
         .)
        </p>
        <p>
         Tumors involving the esophagogastric junction (EGJ) with the tumor epicenter no more than 2 cm into the proximal stomach are staged as esophageal cancers  (
         <a class="graphic graphic_table graphicRef111351" href="/z/d/graphic/111351.html" rel="external">
          table 2
         </a>
         ). In contrast, EGJ tumors with their epicenters located more than 2 cm into the proximal stomach are staged as stomach cancers, as are all cardia cancers not involving the EGJ, even if they are within 2 cm of the EGJ. Thus, regardless of histology and Siewert type, esophageal tumors arising in the cervical, thoracic, or abdominal esophagus, and those involving the EGJ that have an epicenter within 2 cm of the EGJ, share the same criteria for T stage, N stage, and M stage designation  (
         <a class="graphic graphic_table graphicRef111221" href="/z/d/graphic/111221.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         The TNM and Siewert  (
         <a class="graphic graphic_figure graphicRef101001" href="/z/d/graphic/101001.html" rel="external">
          figure 13
         </a>
         ) classifications are reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2502.html" rel="external">
          "Clinical manifestations, diagnosis, and staging of esophageal cancer", section on 'TNM staging criteria'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16226.html" rel="external">
          "Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas", section on 'Definition and classification'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H32960269">
         <span class="h1">
          PRETREATMENT EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Precise pretreatment staging guides multidisciplinary management decisions, including a surgical resection [
         <a href="#rid7">
          7
         </a>
         ]. Pretreatment evaluation, including endoscopic biopsy, computed tomography (CT) of the chest and abdomen, endoscopic ultrasound (EUS), positron emission tomography (PET), and diagnostic laparoscopy and thoracoscopy, is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/2502.html" rel="external">
          "Clinical manifestations, diagnosis, and staging of esophageal cancer", section on 'Pretreatment staging evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16226.html" rel="external">
          "Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas", section on 'Pretreatment staging evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7376975">
         <span class="h1">
          SELECTION OF OPERATIVE CANDIDATES
         </span>
         <span class="headingEndMark">
          —
         </span>
         A surgical resection is the standard treatment approach for patients with an early esophageal cancer, but its utility as a monotherapy has been challenged [
         <a href="#rid14">
          14,15
         </a>
         ]. The role of neoadjuvant chemotherapy and radiation therapy as components of multimodality management is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/2478.html" rel="external">
          "Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7395532">
         <span class="h2">
          Criteria for resection
         </span>
        </p>
        <p class="headingAnchor" id="H8510484">
         <span class="h3">
          Esophagectomy as first line of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The indications for an esophagectomy as the initial therapeutic approach to the patient with an esophageal cancer include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with clinical T1N0M0 lesions  (
         <a class="graphic graphic_table graphicRef111221" href="/z/d/graphic/111221.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with
         <strong>
          clinical
         </strong>
         T2N0M0 lesions are candidates in many medical centers. However, the optimal approach to clinical T2N0 disease is debated, with differing guidelines from expert groups as to indications for initial resection versus upfront (neoadjuvant) therapy. (See
         <a class="medical medical_review" href="/z/d/html/2478.html" rel="external">
          "Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus", section on 'Clinical T2N0 disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16226.html" rel="external">
          "Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas", section on 'Patients with clinical T1/2, node-negative disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8510491">
         <span class="h3">
          Esophagectomy following neoadjuvant chemotherapy or chemoradiotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The indications for initial chemoradiotherapy rather than upfront esophagectomy include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with thoracic esophageal or esophagogastric junction tumors and full-thickness (T3) involvement of the esophagus with/without nodal disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Selected patients with T4a disease  (
         <a class="graphic graphic_table graphicRef111221" href="/z/d/graphic/111221.html" rel="external">
          table 1
         </a>
         ) with invasion of local structures (pericardium, pleura, and/or diaphragm only) that can be resected en bloc, and who are without evidence of metastatic disease to other organs (eg, liver, colon). (See
         <a class="local">
          'Indicators of unresectability'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Patients with esophagogastric junction adenocarcinomas might also be considered for upfront chemotherapy alone if they cannot tolerate trimodality therapy, or if there is a high clinical suspicion of occult metastatic disease. (See
         <a class="medical medical_review" href="/z/d/html/16226.html" rel="external">
          "Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas", section on 'Perioperative chemotherapy'
         </a>
         .)
        </p>
        <p>
         For patients undergoing chemoradiotherapy for potentially resectable disease who have a clinical response, the necessity of subsequent surgery is debated. However, surgical resection is generally recommended, particularly for patients with adenocarcinoma, because of the higher local control rates and lesser need for palliative procedures when surgery is a component of therapy. If there was a complete pathologic response to chemoradiation, then it might be reasonable to avoid surgery, but since this only occurs in 20 to 25 percent of cases and it is not possible to reliably identify these patients either by endoscopic ultrasound (EUS) or repeat positron emission tomography (PET) scan, the recommendation is to proceed with resection if the patient is fit for surgery and has not progressed during chemoradiotherapy. (See
         <a class="medical medical_review" href="/z/d/html/2478.html" rel="external">
          "Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus", section on 'Necessity for surgery'
         </a>
         .)
        </p>
        <p>
         Patients who remain resectable according to radiographic restaging evaluation generally undergo resection four to eight weeks following completion of chemotherapy or chemoradiotherapy [
         <a href="#rid16">
          16,17
         </a>
         ]. We generally do not repeat endoscopic ultrasound for reevaluation of T and N staging prior to surgery unless specific clinical questions need to be addressed. (See
         <a class="medical medical_review" href="/z/d/html/2502.html" rel="external">
          "Clinical manifestations, diagnosis, and staging of esophageal cancer"
         </a>
         .)
        </p>
        <p>
         The impact of neoadjuvant chemotherapy or chemoradiotherapy on perioperative morbidity and mortality was addressed in a meta-analysis of 23 randomized trials comparing neoadjuvant therapy versus surgery alone or neoadjuvant chemotherapy versus chemoradiotherapy [
         <a href="#rid18">
          18
         </a>
         ]. Neither neoadjuvant chemotherapy nor chemoradiotherapy increased the risk of total postoperative mortality or morbidity. However, subgroup analysis suggested that patients undergoing neoadjuvant chemoradiotherapy for squamous cell cancer might be at an elevated risk for postoperative mortality relative to those treated by surgery alone (risk ratio 1.95, 95% CI 1.06-3.6).
        </p>
        <p>
         Issues related to postchemoradiotherapy surgery in patients undergoing definitive chemoradiotherapy for locally advanced unresectable esophageal cancer are addressed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2472.html" rel="external">
          "Management of locally advanced, unresectable and inoperable esophageal cancer", section on 'Role of postchemoradiotherapy surgery'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8510535">
         <span class="h2">
          Relative contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The relative contraindications to an esophagectomy include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Advanced age – Advanced age is associated with greater morbidity following esophagectomy. However, age alone should not determine operability, as selected older patients have similar outcomes to younger patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Comorbid illness – Comorbid illnesses increase the risk of postoperative complications (eg, cardiorespiratory complications, anastomotic leakage, reoperation rates, wound infection) and death following esophagectomy. Obesity is not associated with any increase in overall morbidity following esophagectomy and should not be considered a contraindication for esophagectomy [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7383708">
         <span class="h2">
          Indicators of unresectability
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of metastatic disease, such as peritoneal, lung, bone, adrenal, brain, or liver metastases, or extraregional lymph node spread (eg, paraaortic or mesenteric lymphadenopathy), precludes an attempt at resection. The regional lymph nodes for all locations in the esophagus, including the cervical esophagus and esophagogastric junction, extend from the periesophageal cervical nodes to celiac nodes. Celiac nodal metastases and mediastinal/supraclavicular nodes are scored as regional nodal disease in the tumor, node, metastasis (TNM) staging system, regardless of the primary tumor location  (
         <a class="graphic graphic_figure graphicRef111319" href="/z/d/graphic/111319.html" rel="external">
          figure 12
         </a>
         ) [
         <a href="#rid13">
          13
         </a>
         ]; it is the number of involved nodes rather than location that determines the N stage  (
         <a class="graphic graphic_table graphicRef111221" href="/z/d/graphic/111221.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2502.html" rel="external">
          "Clinical manifestations, diagnosis, and staging of esophageal cancer", section on 'Regional lymph nodes'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2472.html" rel="external">
          "Management of locally advanced, unresectable and inoperable esophageal cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1459411">
         <span class="h1">
          PREHABILITATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intensive preoperative respiratory rehabilitation and nutritional support reduce postoperative pulmonary complications after an esophagectomy [
         <a href="#rid20">
          20,21
         </a>
         ]. A retrospective cohort study of 100 patients undergoing an esophagectomy found that patients managed with preoperative respiratory rehabilitation (n = 63) for seven days had a lower rate of postoperative pulmonary complications compared with patients not receiving preoperative respiratory rehabilitation (6 versus 24 percent) [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1463.html" rel="external">
          "Pulmonary rehabilitation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H32960293">
         <span class="h1">
          OPERATIVE PROCEDURES
         </span>
        </p>
        <p class="headingAnchor" id="H7377428">
         <span class="h2">
          Cervical esophageal cancer resection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Carcinoma of the cervical esophagus presents a unique management situation, and most patients are treated primarily by chemotherapy and radiation therapy. (See
         <a class="medical medical_review" href="/z/d/html/2478.html" rel="external">
          "Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus", section on 'Cervical esophagus tumors'
         </a>
         .)
        </p>
        <p>
         For patients who fail chemotherapy/radiation therapy or who opt for a surgical resection rather than neoadjuvant therapy, a surgical resection usually requires removal of portions of the pharynx, the larynx, the thyroid gland, and portions of the proximal esophagus. This one-stage, three-phase operation requires cervical, abdominal, and thoracic incisions and a permanent terminal tracheostomy. Alternatively, a transhiatal approach is reasonable. In addition, bilateral radical neck dissections are generally performed [
         <a href="#rid23">
          23-33
         </a>
         ]. If there is sufficient margin on the upper esophageal sphincter  (
         <a class="graphic graphic_figure graphicRef111260" href="/z/d/graphic/111260.html" rel="external">
          figure 6
         </a>
         ), we perform a tri-incisional esophagectomy with a hand-sewn anastomosis to preserve esophageal length. (See
         <a class="local">
          'Tri-incisional esophagectomy'
         </a>
         below.)
        </p>
        <p>
         Restoration of gastrointestinal tract continuity is accomplished with a gastric pull-up and anastomosis to the pharynx. For tumors confined to the proximal portion of the cervical esophagus, with a sufficient distal resection margin, a free jejunal interposition graft or a deltopectoral or pectoralis major myocutaneous flap are alternative reconstructive options. Free jejunal grafts are advantageous because this approach avoids mediastinal dissection, although expertise in performing microvascular anastomosis is required. Graft necrosis, fistula formation, and later graft strictures are specific problems. When compared with gastric pull-up procedures, graft survival and leakage rates are similar. Complications of esophageal procedures are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15058.html" rel="external">
          "Complications of esophageal resection", section on 'Conduit complications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7377436">
         <span class="h2">
          Thoracic cancer resection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with either adenocarcinoma or squamous cell carcinoma involving the middle or lower third of the esophagus, with the exception of gastroesophageal junction cancers, generally require a total esophagectomy because of the risk of submucosal skip lesions [
         <a href="#rid34">
          34-36
         </a>
         ]. In selected cases, such as a superficial or early invasive esophageal cancer arising distally in the setting of Barrett's esophagus, a more limited resection (eg, an anastomosis in the thorax or a less radical resection such as a transhiatal resection) can be performed. However, the optimal surgical approach in these clinical settings is unknown [
         <a href="#rid37">
          37-39
         </a>
         ]. If a limited resection is performed, intraoperative histologic analysis of the surgical margins must show no evidence of Barrett's changes. (See
         <a class="medical medical_review" href="/z/d/html/2494.html" rel="external">
          "Management of superficial esophageal cancer"
         </a>
         .)
        </p>
        <p>
         Esophagectomy is a technically difficult operation, and the complication rate is high due to the anatomic challenges of the procedure. The choice of surgical approach depends upon many factors, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumor location, length, submucosal extension, and adherence to surrounding structures
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The type or extent of lymphadenectomy desired
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The conduit to be used to restore gastrointestinal continuity
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Postoperative bile reflux
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The preference of the surgeon
        </p>
        <p>
        </p>
        <p>
         The transhiatal, Ivor-Lewis (transthoracic), and tri-incisional esophagectomy procedures are the most commonly performed esophagectomies in North America, while an esophagectomy and an extended (three-field) lymphadenectomy is commonly performed in Asia [
         <a href="#rid40">
          40-46
         </a>
         ].
        </p>
        <p>
         Although the gastric interposition is most commonly used as a conduit for reconstruction following esophagectomy, the jejunum or the colon can also be used as the conduit [
         <a href="#rid47">
          47-51
         </a>
         ]. These conduits are resistant to the effects of gastric acid, and they have a shape similar to that of the native esophagus. However, their use requires two additional anastomoses, and in the case of the jejunal interposition, the fixed mesenteric length limits transposition to the proximal esophagus.
        </p>
        <p class="headingAnchor" id="H7378087">
         <span class="h3">
          Transhiatal esophagectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         A transhiatal esophagectomy (THE) can be performed to resect cervical, thoracic, and esophagogastric junction (EGJ) esophageal cancers; it is performed through an upper midline laparotomy incision and a left neck incision, typically without a thoracotomy [
         <a href="#rid52">
          52,53
         </a>
         ]. The thoracic esophagus is bluntly dissected through the diaphragmatic hiatus superiorly and via the neck inferiorly. A cervical anastomosis is created most often with a gastric pull-up approach. Disadvantages include the inability to perform a full thoracic lymphadenectomy and lack of visualization of the midthoracic dissection  (
         <a class="graphic graphic_figure graphicRef83471" href="/z/d/graphic/83471.html" rel="external">
          figure 11
         </a>
         ).
        </p>
        <p>
         In the largest prospective database series of 2007 patients, the in-hospital mortality rate decreased in the 1998 to 2006 cohort (n = 944 patients) compared with the 1976 to 1998 cohort (1 versus 4 percent) [
         <a href="#rid54">
          54
         </a>
         ]. In
         <strong>
         </strong>
         addition, the anastomotic leak rate was also lower in the 1998 to 2006 cohort (9 versus 14 percent).
         <strong>
         </strong>
         Other postoperative complications included atelectasis and pneumonia (2 percent) and intrathoracic hemorrhage, recurrent laryngeal nerve (RLN) paralysis, chylothorax, and tracheal laceration in &lt;1 percent each. Similar results have been noted in other large series [
         <a href="#rid52">
          52,55-59
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7378094">
         <span class="h3">
          Ivor-Lewis transthoracic esophagectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Ivor-Lewis transthoracic esophagectomy can be used to resect cancers in the lower third of the esophagus but is not the optimal approach for cancers located in the middle third because of the limited proximal margin that can be achieved. This procedure combines a laparotomy with a right thoracotomy and an intrathoracic esophagogastric anastomosis. This approach permits direct visualization of the thoracic esophagus and allows the surgeon to perform a full thoracic lymphadenectomy. We prefer a minimally invasive Ivor-Lewis approach to a thoracotomy.
        </p>
        <p>
         Disadvantages of the transthoracic esophagectomy include a limitation to the length of proximal esophagus that can be resected to achieve a histologically negative resection margin, an intrathoracic location of the esophagogastric anastomosis, and a 3 to 20 percent risk of severe bile reflux [
         <a href="#rid55">
          55,60
         </a>
         ]. A leak occurring at the intrathoracic anastomosis has been associated with morbidity and mortality rates as high as 64 percent [
         <a href="#rid61">
          61-66
         </a>
         ]. With current techniques, mortality rates are substantially lower [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
         Many centers report favorable results using the conventional Ivor-Lewis esophagectomy with a right thoracic anastomosis [
         <a href="#rid58">
          58,68-74
         </a>
         ]. Prospective comparisons [
         <a href="#rid59">
          59,75-79
         </a>
         ], plus at least one meta-analysis [
         <a href="#rid80">
          80
         </a>
         ], suggest similar long-term outcomes compared to THE [
         <a href="#rid73">
          73
         </a>
         ]. In one of the largest series of 228 patients undergoing an Ivor-Lewis subtotal esophagectomy, the perioperative mortality rate was 4 percent, and major respiratory and cardiovascular and/or thromboembolic complications occurred in 17 and 7 percent, respectively [
         <a href="#rid73">
          73
         </a>
         ]. Nine patients (4 percent) developed a mediastinal leak, which was anastomotic in five and due to either an ischemic gastric conduit or gastrotomy dehiscence in the remainder. Only one patient developed a chyle leak. (See
         <a class="medical medical_review" href="/z/d/html/15058.html" rel="external">
          "Complications of esophageal resection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H89042319">
         <span class="h3">
          Modified Ivor-Lewis transthoracic esophagectomy (left thoracoabdominal esophagogastrectomy)
         </span>
         <span class="headingEndMark">
          —
         </span>
         A modification of the Ivor-Lewis transthoracic esophagectomy includes a left thoracoabdominal incision with a gastric pull-up and an esophagogastric anastomosis in the left chest [
         <a href="#rid81">
          81
         </a>
         ]. This approach is most useful for tumors involving the gastroesophageal junction. Only one incision is required, but disadvantages include a high incidence of complications such as postoperative reflux and limitation of the proximal esophageal margin by the aortic arch.
        </p>
        <p class="headingAnchor" id="H7378101">
         <span class="h3">
          Tri-incisional esophagectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The tri-incisional esophagectomy combines the transhiatal and transthoracic approaches into a transthoracic total esophagectomy with a thoracic lymphadenectomy and cervical esophagogastric anastomosis [
         <a href="#rid82">
          82-86
         </a>
         ]. The three-incisional technique allows the surgeon to perform a complete two-field (mediastinal and upper abdominal) lymphadenectomy under direct vision and a cervical esophagogastric anastomosis. We prefer a thorascopic approach to the chest rather than a thoracotomy to minimize the risk of respiratory complications. (See
         <a class="medical medical_review" href="/z/d/html/15058.html" rel="external">
          "Complications of esophageal resection", section on 'Pulmonary'
         </a>
         .)
        </p>
        <p>
         The following surgical oncology principles are used to perform a tri-incisional esophagectomy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thoracotomy – A right posterolateral thoracotomy or a thoracoscopy is performed first to assess resectability and exclude local invasion of contiguous structures. An en bloc resection is performed that includes the esophagus and mediastinal  (
         <a class="graphic graphic_figure graphicRef69492" href="/z/d/graphic/69492.html" rel="external">
          figure 14
         </a>
         ) and upper abdominal lymph nodes  (
         <a class="graphic graphic_figure graphicRef83510" href="/z/d/graphic/83510.html" rel="external">
          figure 15
         </a>
         ), including the right paratracheal, subcarinal, periesophageal, and celiac axis lymph nodes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Laparotomy – The abdomen is explored to exclude metastatic disease, and the stomach is mobilized in preparation for the construction of the gastric conduit.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neck incision – A left neck exposure is preferred for the esophagogastric anastomosis since this approach reduces the risk of injury to the RLN  (
         <a class="graphic graphic_figure graphicRef64619" href="/z/d/graphic/64619.html" rel="external">
          figure 16
         </a>
         ) [
         <a href="#rid55">
          55,68,69,82,87
         </a>
         ]. The left RLN recurs lower (around the aortic arch) than the right RLN, which recurs around the subclavian artery and is therefore more likely to be injured from a right neck approach.
        </p>
        <p>
        </p>
        <p>
         The advantages of a neck anastomosis include easier management of a possible anastomotic leak, lower incidence of reflux, more extensive proximal resection margin, and location outside of radiation ports if administered preoperatively. (See
         <a class="medical medical_review" href="/z/d/html/15058.html" rel="external">
          "Complications of esophageal resection", section on 'Conduit complications'
         </a>
         .)
        </p>
        <p>
         In our reported series of 250 patients treated with the combined approach, there were no intraoperative deaths, and the perioperative mortality rate was 3.6 percent (9 of 250) [
         <a href="#rid82">
          82
         </a>
         ]. The cause of death was pneumonia and progressive respiratory failure in three, aspiration and respiratory arrest in one, pulmonary embolism in two, sepsis in the setting of conduit leak and empyema in one, ischemic bowel and multisystem organ failure in one, and cirrhosis in the setting of ischemic necrosis of the conduit in one. Early postoperative complications occurred in 124 of 250 patients (50 percent); they were considered major in 83. An anastomotic or conduit leak (from either conduit necrosis or leak from the staple line) occurred in 14 and 5 patients (5.6 and 2 percent, respectively).
        </p>
        <p class="headingAnchor" id="H7377444">
         <span class="h2">
          Esophagogastric junction cancer resection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Esophageal cancers at the EGJ or intra-abdominal esophagus have been traditionally managed surgically with either an esophagectomy with partial gastrectomy or an extended gastrectomy, with or without thoracotomy  (
         <a class="graphic graphic_figure graphicRef55061" href="/z/d/graphic/55061.html" rel="external">
          figure 3
         </a>
         ). Regardless of the approach, complete (R0) resection, a 4 cm (distal) gastric margin, a 5 cm esophageal margin, and resection of at least 15 nodes in basins appropriate for the primary tumor location are necessary [
         <a href="#rid88">
          88,89
         </a>
         ]. The extent of the esophageal resection that can be achieved solely via a transabdominal approach without thoracoabdominal incision or transhiatal esophagectomy is limited, and therefore this approach is not accepted for tumors that involve the distal esophagus, due to difficulties in achieving an adequate negative proximal margin.
        </p>
        <p>
         The contemporary operative approach for EGJ cancer is based upon findings from two surgical phase III trials [
         <a href="#rid90">
          90,91
         </a>
         ], which randomly assigned patients to the operative procedure on the basis of the Siewert classification of EGJ adenocarcinoma  (
         <a class="graphic graphic_figure graphicRef64783" href="/z/d/graphic/64783.html" rel="external">
          figure 17
         </a>
         ) [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A phase III Dutch trial randomly assigned 220 patients with Siewert type I or II EGJ adenocarcinoma to THE versus extended thoracic resection (transthoracic esophagectomy with an extended en bloc lymphadenectomy via the right thoracic approach [RTA]) [
         <a href="#rid77">
          77,90
         </a>
         ]. In-hospital mortality did not differ between the groups, but pulmonary complications and postoperative chylous leakage were significantly more frequent after RTA; in addition, intensive care unit (ICU) and total hospital stays were also longer in this group [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Five-year overall survival rates were similar (36 versus 34 percent for RTA and THE, respectively), but there was a trend toward better survival with extended thoracic resection in the patients with a type I tumor (five-year survival 51 versus 37 percent, p = 0.33). Also, for patients with a limited number of positive lymph nodes (one to eight), the transthoracic approach had a better five-year locoregional disease-free survival. The authors concluded that given the greater hazards associated with extended transthoracic resection, it could only be recommended for patients with type I and not type II tumors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A Japanese trial (JCOG 9502) compared THE versus extended esophagectomy using a left thoracoabdominal approach (LTA) for patients with type II or III adenocarcinoma of the EGJ [
         <a href="#rid91">
          91
         </a>
         ]. Patients in the THE group received a total gastrectomy plus a D2 lymphadenectomy (including splenectomy) and para-aortic lymph node dissection. This approach involved a laparotomy only and therefore only resection of the lower esophagus. Thoracotomy was utilized only if there was a positive proximal margin. (See
         <a class="medical medical_review" href="/z/d/html/2481.html" rel="external">
          "Surgical management of invasive gastric cancer", section on 'Extent of lymph node dissection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The patients in the LTA group underwent thorough mediastinal nodal dissection below the left inferior pulmonary vein as well as the same lymphadenectomy procedure in the abdominal cavity as the THE group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The trial closed prematurely when a planned interim analysis concluded that it was unlikely that LTA would be significantly better than THE. Five-year survival rate was lower in the LTA group (38 versus 52 percent), although the difference was not statistically significant. The difference was maintained with long-term follow-up (10 year survival 24 versus 37 percent), but it remained not statistically significant [
         <a href="#rid93">
          93
         </a>
         ]. In addition, complications were observed more frequently after LTA, and in-hospital mortality was higher (4 versus 0 percent) [
         <a href="#rid91">
          91
         </a>
         ]. The authors concluded that LTA could not be recommended for type II or III tumors.
        </p>
        <p>
        </p>
        <p>
         Based upon the results of these, the surgical approach for resection is summarized as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with Siewert type I tumors should preferentially undergo a transthoracic en bloc esophagectomy and partial gastrectomy with two-field lymphadenectomy. Lymphadenectomy is important to assess disease stage and evaluate response to neoadjuvant therapy with minimal added risk in morbidity or mortality rates. Other reasonable options include a transhiatal approach, which does not include a lymphadenectomy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with Siewert type II tumors should undergo an Ivor-Lewis esophagectomy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with Siewert type III tumors should undergo a total gastrectomy with a transhiatal resection of the distal esophagus with lymphadenectomy of the lower mediastinum and an extended lymph node dissection including nodes along the hepatic, left gastric, celiac, and splenic arteries as well as those in the splenic hilum. (See
         <a class="medical medical_review" href="/z/d/html/2481.html" rel="external">
          "Surgical management of invasive gastric cancer", section on 'Extent of lymph node dissection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The operation should be extended into a transhiatal or transthoracic esophagectomy in the setting of a positive proximal resection margin at frozen section examination.
        </p>
        <p class="headingAnchor" id="H89045791">
         <span class="h1">
          PRINCIPLES OF SURGICAL RESECTION
         </span>
        </p>
        <p class="headingAnchor" id="H191450580">
         <span class="h2">
          Minimally invasive approaches
         </span>
         <span class="headingEndMark">
          —
         </span>
         An Ivor-Lewis esophagectomy can be performed through an open, totally minimally invasive (thoracoscopic/laparoscopic), or hybrid approach. The hybrid approach can either combine thoracoscopic resection of the thoracic esophagus and mediastinal nodes with open laparotomy or combine laparoscopic resection of the intra-abdominal esophagus, stomach, and lymph nodes with an open right thoracotomy. The transhiatal esophagectomy can be performed open or laparoscopically.
        </p>
        <p>
         Early reports indicated that minimally invasive esophagectomy was safe [
         <a href="#rid94">
          94-100
         </a>
         ], but benefit in terms of long-term outcomes compared with open esophagectomy were uncertain [
         <a href="#rid101">
          101
         </a>
         ]. More studies and two trials associated totally minimally invasive and hybrid Ivor-Lewis esophagectomy with fewer postoperative pulmonary complications and similar oncologic outcomes compared with open surgery, at least in the intermediate term (up to three-year follow-up). A 2019 systematic review and meta-analysis of 55 studies, including over 14,000 patients, concluded that minimally invasive esophagectomy was associated with an 18 percent
         <strong>
          lower
         </strong>
         five-year all-cause mortality compared with open esophagectomy (hazard ratio 0.82, 95% CI 0.76-0.88) [
         <a href="#rid102">
          102
         </a>
         ]. Additional data are available from an analysis of over 5500 patients from the National Cancer Database who underwent esophagectomy between 2010 and 2015, which found comparable survival between minimally invasive, robotic-assisted, and open approaches [
         <a href="#rid103">
          103
         </a>
         ]. Both minimally invasive and robotic approaches produced a higher median lymph node yield than the open approach.
        </p>
        <p class="headingAnchor" id="H2887136128">
         <span class="h3">
          Totally minimally invasive Ivor-Lewis esophagectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         A totally minimally invasive approach to Ivor-Lewis esophagectomy is technically feasible, but data for oncologic outcomes are limited due to short follow-up and the small number of patients evaluated [
         <a href="#rid97">
          97,98,104-110
         </a>
         ].
        </p>
        <p>
         The best evidence comes from the TIME trial, which found that patients undergoing a totally minimally invasive esophagectomy have a better perioperative hospital course. In this multicenter, randomized trial of 115 patients with esophageal cancer, patients undergoing a minimally invasive esophagectomy had a lower rate of pulmonary infections in-hospital compared with patients undergoing an open esophagectomy (12 versus 34 percent, relative risk [RR] 0.35, 95% CI 0.16-0.78) [
         <a href="#rid111">
          111
         </a>
         ]. Patients undergoing minimally invasive esophagectomy also had a lower perioperative (first two weeks after surgery) rate of pulmonary infections compared with patients undergoing an open esophagectomy (9 versus 29 percent, RR 0.30, 95% CI 0.12-0.76). A follow-up study showed similar three-year disease-free (36 versus 40 percent) and overall (40 versus 51 percent) survival for patients who underwent open surgery versus minimally invasive esophagectomy [
         <a href="#rid112">
          112
         </a>
         ].
        </p>
        <p>
         The robot-assisted minimally invasive thoracolaparoscopic esophagectomy (RAMIE) technique was evaluated in another trial of 112 patients with esophageal cancer [
         <a href="#rid113">
          113
         </a>
         ]. Compared with open transthoracic esophagectomy, RAMIE resulted in fewer complications, faster functional recovery, and better short-term quality of life. Oncologic outcomes were comparable at a median follow-up of 40 months.
        </p>
        <p>
         The oncologic outcomes of totally minimally invasive esophagectomy were also addressed in three other nonrandomized series:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A propensity score-matched analysis of 184 patients also found comparable early outcomes between robot-assisted versus thoracoscopic-assisted Ivor-Lewis esophagectomy for the treatment of middle and distal esophageal cancer [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a British series of 65 patients who underwent totally minimally invasive esophagectomy for invasive esophageal cancer, the two-year overall and disease-free survival rates were 81 and 74 percent, respectively. Recurrence was documented in 14 patients, 11 of which were distant recurrences [
         <a href="#rid97">
          97
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective Australian series compared outcomes among 114 patients who had open esophagectomy, 309 patients who had thoracoscopic-assisted surgery, and 23 who had a totally minimally invasive esophagectomy [
         <a href="#rid115">
          115
         </a>
         ]. There were no differences in the rate of margin positivity or the number of lymph nodes retrieved in any of the groups and no differences in the time to recurrence or median or three-year overall survival when patients were compared stage for stage.
        </p>
        <p>
        </p>
        <p>
         Although data suggest potential benefit for a totally minimally invasive approach to Ivor-Lewis esophagectomy, they are not sufficient to conclude that this is a standard approach. Additional data, particularly regarding long-term complications and oncologic outcomes, are needed before it can be concluded that totally minimally invasive Ivor-Lewis esophagectomy should replace open esophagectomy. For now, the National Comprehensive Cancer Network (NCCN) guidelines regard minimally invasive esophagectomy as an acceptable approach for esophageal cancer. However, minimally invasive esophagectomy should only be attempted by qualified surgeons; these procedures come with a steep learning curve and high learning-associated morbidity [
         <a href="#rid116">
          116,117
         </a>
         ]. There is evidence that the outcomes improve with experience [
         <a href="#rid118">
          118
         </a>
         ].
        </p>
        <p>
         The technique of totally minimally invasive Ivor-Lewis esophagectomy with intrathoracic anastomosis is discussed in another topic. (See
         <a class="medical medical_review" href="/z/d/html/128278.html" rel="external">
          "Minimally invasive esophagectomy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2019654072">
         <span class="h3">
          Hybrid Ivor-Lewis esophagectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         A thoracoscopic approach to mobilization of the intrathoracic portion of the esophagus and node dissection is an accepted alternative to open thoracotomy in centers with surgeon expertise in these techniques and is combined with open laparotomy for completion of the mobilization and upper abdominal node dissection. This represents the most popular minimally invasive esophagectomy technique with the most extensive published experience [
         <a href="#rid95">
          95,96,119-121
         </a>
         ], despite none of the studies being prospective or randomized. Relative contraindications to thoracoscopic surgery include inadequate pulmonary function, extensive pleural adhesions, prior pneumonectomy, bulky tumors, and locally infiltrative tumors, particularly those with airway involvement [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
         An alternative hybrid approach combines laparoscopic resection of the intra-abdominal esophagus, stomach, and lymph nodes with an open right thoracotomy. The purported advantage of this approach is reduced risk of intraoperative pulmonary complications. The benefit of this approach was shown in a randomized trial of 207 patients with cancer in the middle or lower third of the esophagus, in which a hybrid approach of laparoscopic gastric mobilization combined with open right thoracotomy resulted in fewer major intraoperative and postoperative complications (36 versus 64 percent), especially pulmonary complications (18 versus 30 percent), compared with open esophagectomy [
         <a href="#rid122">
          122
         </a>
         ]. The overall (67 percent hybrid versus 55 percent open) and disease-free survival (57 versus 48 percent) at three years was not affected by the operative approach.
        </p>
        <p class="headingAnchor" id="H2753612646">
         <span class="h3">
          Laparoscopic transhiatal esophagectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The transhiatal esophagectomy can be performed open or laparoscopically. A 2016 Cochrane systemic review and meta-analysis of six observational studies (five retrospective) concluded that laparoscopic transhiatal esophagectomy was associated with fewer overall (risk ratio 0.64, 95% CI 0.48-0.86) and serious complications (risk ratio 0.49, 95% CI 0.24-0.99), as well as shorter hospital stays (by three days) compared with open transhiatal esophagectomy [
         <a href="#rid123">
          123
         </a>
         ]. However, randomized prospective trials are needed to determine the optimal approach to transhiatal esophagectomy.
        </p>
        <p class="headingAnchor" id="H29382338">
         <span class="h2">
          Circumferential resection margin
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognostic role of a positive circumferential resection margin (CRM) for patients with esophageal cancer was unclear, in part due to a lack of clear definition of a positive margin [
         <a href="#rid124">
          124
         </a>
         ]. The College of American Pathologists (CAP) defines a positive CRM as the presence of esophageal cancer at the resection margin [
         <a href="#rid125">
          125
         </a>
         ]. However, the United Kingdom Royal College of Pathologists (RCP) defines a positive CRM as the presence of esophageal cancer within 1 mm of the resection margin [
         <a href="#rid126">
          126,127
         </a>
         ].
        </p>
        <p>
         CAP criteria differentiate a higher-risk group of patients with resectable esophageal cancer than the RCP criteria. A meta-analysis of 14 cohort studies including 3566 patients with resectable esophageal cancer found the overall
         <strong>
          five-year mortality rates
         </strong>
         were higher for patients with a positive CRM compared with a negative CRM [
         <a href="#rid124">
          124
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CAP criteria – 15.3 percent positive margins (173/1133), odds ratio (OR) 4.02, 95% CI 2.25-7.20, p &lt;0.001
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         RCP criteria – 36.5 percent positive margins (889/2433), OR 2.52, 95% CI 1.96-3.25, p &lt;0.001
        </p>
        <p>
        </p>
        <p>
         In addition, patients with CRM involvement between 0.1 and 1 mm of the resection margin had a significantly higher five-year mortality rate compared with patients with tumor more than 1 mm of the resection margin (OR 2.05, 95% CI 1.41-2.99, p &lt;0.001).
        </p>
        <p class="headingAnchor" id="H7383196">
         <span class="h2">
          Extent of lymphadenectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The appropriate extent of lymphadenectomy during esophageal cancer surgery is debated. The minimum number of lymph nodes that should be removed during potentially curative esophagectomy has not been established. However, as many lymph nodes should be removed as is feasible since more extensive lymphadenectomy has been associated with better survival [
         <a href="#rid46">
          46,128-132
         </a>
         ]. For example, in a retrospective review of 972 patients with node-negative esophageal cancer, the five-year disease-specific survival was 55 percent when fewer than 11 nodes were resected, 66 percent for 11 to 17 nodes resected, and 75 percent for 18 or more nodes resected [
         <a href="#rid128">
          128
         </a>
         ]. A greater number of retrieved lymph nodes generally reflects more accurate staging, which generally comes with more extensive resections.
        </p>
        <p>
         Many high-volume surgical centers routinely perform en bloc esophagectomy with a two-field (mediastinal, upper abdomen) lymph node dissection in the belief that this contributes to better locoregional control because of removal of metastatic lymph nodes. An even more extensive lymphadenectomy, three-field lymphadenectomy of the mediastinal, abdominal, and cervical nodes, is commonly practiced in Asian countries for upper thoracic esophageal cancers [
         <a href="#rid40">
          40-46,133
         </a>
         ]. In a retrospective review of 1361 patients with squamous cell carcinoma of the thoracic esophagus, the frequency of nodal metastasis was neck (9.8 percent), upper mediastinum (18.0 percent), middle mediastinum (18.9 percent), lower mediastinum (11.8 percent), and upper abdomen (28.4 percent) [
         <a href="#rid133">
          133
         </a>
         ]. However, while this approach increases the accuracy of staging, whether local control or survival is improved compared with two-field lymphadenectomy is uncertain.
        </p>
        <p>
         Proponents of extended lymphadenectomy emphasize the relationship between total lymph node count and prognosis [
         <a href="#rid46">
          46,129-131
         </a>
         ] and quote long-term survival rates as evidence of its therapeutic benefit. As an example, in one American series of 80 patients undergoing this technique in conjunction with en bloc esophagectomy, the overall five-year survival rate was 51 percent (88 percent for node-negative and 33 percent for node-positive patients) [
         <a href="#rid134">
          134
         </a>
         ]. However, since the extent of lymph node dissection can affect the assignment of the final stage of disease, this resulting stage migration phenomenon hampers a stage-by-stage comparison between different forms of surgical resection [
         <a href="#rid135">
          135
         </a>
         ]. Furthermore, although unsuspected metastases in the recurrent laryngeal or cervical nodes were detected in 36 percent of patients in the above-noted series [
         <a href="#rid134">
          134
         </a>
         ], others report a low incidence of cervical nodal recurrence following a two-field lymphadenectomy [
         <a href="#rid136">
          136
         </a>
         ]. The location of the tumor (upper versus middle to lower third) may have an influence on the frequency of finding cervical nodal metastases [
         <a href="#rid137">
          137
         </a>
         ].
        </p>
        <p>
         At least two randomized trials have compared different extents of lymphadenectomy during esophageal cancer surgery, although neither provides a conclusive result as to the benefit of extended lymphadenectomy [
         <a href="#rid90">
          90,138
         </a>
         ]. In the United States, en bloc resection of the mediastinal and upper abdominal lymph nodes is considered a standard component of transthoracic esophagectomy, and a three-field lymphadenectomy is not considered a standard treatment for patients with esophageal cancer. However, if a lymph node dissection is not done, then lymph node sampling should be carried out to accurately stage the patient and to gauge the response to induction treatment in patients enrolled in trials using neoadjuvant therapy.
        </p>
        <p class="headingAnchor" id="H1813059">
         <span class="h2">
          Hand-sewn versus stapled anastomosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anastomotic closure techniques include hand-sewn (single versus double layer), stapled (circular versus side-to-side linear), and hybrid linear stapled technique, with surgeon experience likely being the most important determinant at present [
         <a href="#rid139">
          139-148
         </a>
         ]. For example, in a meta-analysis of 12 randomized controlled trials that included 1407 patients, the rate of anastomotic leak was similar for a circular stapled anastomosis compared with a hand-sewn anastomosis (OR 1.02, 95% CI 0.66-1.59) [
         <a href="#rid148">
          148
         </a>
         ]. However, a stapled anastomosis was associated with a significantly higher rate of anastomotic stricture (OR 1.67, 95% CI 1.16-2.42).
        </p>
        <p>
         A hybrid linear stapled technique was developed in the 1990s that demonstrated a 65 percent increase in the anastomotic cross-sectional area [
         <a href="#rid145">
          145
         </a>
         ] and reduced morbidity for patients undergoing a cervical esophagogastric anastomosis [
         <a href="#rid147">
          147
         </a>
         ]. In a review of 274 patients, those undergoing a hybrid anastomosis (modified Collard technique, n = 86 patients) had fewer cervical wound infections compared with patients undergoing a hand-sewn anastomosis (8 versus 29 percent) [
         <a href="#rid147">
          147
         </a>
         ]. Patients undergoing a hybrid anastomosis had a statistically similar leak rate but required fewer anastomotic dilatations (4 versus 11 percent, mean 2.4 versus 4.1 per patient, respectively).
        </p>
        <p class="headingAnchor" id="H1813131">
         <span class="h2">
          Cervical versus thoracic anastomosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         When performed using a standardized technique, cervical and thoracic esophagogastric anastomoses are equally safe [
         <a href="#rid141">
          141,149
         </a>
         ]. In a randomized trial of 83 patients undergoing an esophagogastric anastomosis, the additional 5 cm esophageal resection to permit a cervical esophagogastric anastomosis did not increase tumor removal and survival or adversely influence morbidity, anastomotic diameter, or body weight development compared with a thoracic esophagogastric anastomosis [
         <a href="#rid149">
          149
         </a>
         ].
        </p>
        <p>
         At present, the choice of anastomotic location remains clinician dependent. A cervical anastomosis has a higher leak rate and risk of injury to the recurrent laryngeal nerve [
         <a href="#rid59">
          59,141,150
         </a>
         ]. However, the anatomic confines of the neck and thoracic inlet limit surrounding tissue contamination and thus limit morbidity. A systematic review of four clinical trials that included 267 patients found that patients undergoing a cervical esophagogastric anastomosis (n = 132) had a higher rate of anastomotic leak compared with those undergoing a thoracic esophagogastric anastomosis (18 versus 4 percent, OR 3.43, 95% CI 1.09-10.78) [
         <a href="#rid141">
          141
         </a>
         ]. A cervical esophagogastric anastomosis has a significantly higher rate of recurrent laryngeal nerve injury (OR 7.14, 95% CI 1.75-29.14), but there was no difference in the rate of pulmonary complications, perioperative mortality, benign stricture formation, or tumor recurrence at the anastomotic site. (See
         <a class="medical medical_review" href="/z/d/html/15058.html" rel="external">
          "Complications of esophageal resection", section on 'Anastomotic leak'
         </a>
         .)
        </p>
        <p>
         Additionally, utilizing the Surveillance, Epidemiology, and End Results (SEER) database, a retrospective cohort review was performed comparing 225 transhiatal resections to 643 transthoracic resections [
         <a href="#rid59">
          59
         </a>
         ]. The unadjusted anastomotic complication rate, identified by need for postoperative endoscopic dilation, was higher (43.1 versus 34.5 percent; p = 0.02) in the transhiatal group; however, there was no significant difference in risk-adjusted five-year survival between groups.
        </p>
        <p class="headingAnchor" id="H191451188">
         <span class="h2">
          Orthotopic placement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Orthotopic placement of the neoesophagus in the posterior mediastinum is generally preferred by most thoracic surgeons. A meta-analysis of trials comparing the posterior mediastinal route and the retrosternal route was performed and was unable to demonstrate any difference in postoperative morbidity [
         <a href="#rid151">
          151
         </a>
         ]. Other series, however, have revealed a higher anastomotic leak rate in the retrosternal route, likely due to increased length requirements for the conduit as well as compression [
         <a href="#rid54">
          54,152,153
         </a>
         ]. Conduit choice may also affect anastomotic integrity, although the majority of surgeons presently prefer the stomach due to its ease of preparation, robust blood supply, and sufficient length, with alternative conduits, including colon and jejunum, only being chosen out of necessity.
        </p>
        <p class="headingAnchor" id="H191454073">
         <span class="h2">
          Role of pyloroplasty or pyloromyotomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of a pyloroplasty or pyloromyotomy to reduce the risk of gastric outlet obstruction following a gastric pull-up procedure has been challenged by prospective studies and randomized trials, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective study of 242 patients undergoing an esophagectomy with gastric conduit found that patients with a pyloromyotomy (n = 159) did not have significantly lower rates of gastric outlet obstruction compared with those without a pyloromyotomy (9.6 versus 18.2 percent, respectively) [
         <a href="#rid154">
          154
         </a>
         ]. In addition, there was no significant difference for rates of pneumonia or mortality (27.7 versus 19.5 percent, and 2.4 versus 2.5 percent, respectively). Management with pyloric dilation was effective in relieving symptoms in approximately 97 percent of symptomatic patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of nine trials and 553 esophagectomy patients randomized to pyloromyotomy versus none found a lower risk of gastric outlet obstruction for patients treated with a pyloromyotomy (OR 0.18, 95% CI 0.03-0.97, p &lt;0.046) [
         <a href="#rid155">
          155
         </a>
         ]. There was no difference for operative mortality, esophagogastric anastomotic leaks, pulmonary morbidity, or fatal pulmonary aspiration.
        </p>
        <p>
        </p>
        <p>
         Functional conduit disorders and their management are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/15058.html" rel="external">
          "Complications of esophageal resection", section on 'Functional disorders'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H191450878">
         <span class="h2">
          Recurrent laryngeal nerve identification
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recurrent laryngeal nerve (RLN) injury can occur during dissection of the cervical and thoracic esophagus [
         <a href="#rid55">
          55,68,69,87
         </a>
         ]. Rates of injury range from 2 to 17 percent and occur more commonly when a cervical approach is utilized [
         <a href="#rid54">
          54,82,156,157
         </a>
         ]. Principles for the avoidance of RLN injury include precise knowledge of cervical esophageal anatomy  (
         <a class="graphic graphic_figure graphicRef74541" href="/z/d/graphic/74541.html" rel="external">
          figure 18
         </a>
         ), maintaining the plane of dissection as close as possible to the esophagus, and avoidance of metal or rigid retractors along the tracheoesophageal groove.
        </p>
        <p class="headingAnchor" id="H191465190">
         <span class="h2">
          Jejunal feeding tube placement
         </span>
         <span class="headingEndMark">
          —
         </span>
         A feeding jejunostomy tube is inserted at the time of the surgical resection for all patients undergoing an esophagectomy and for select patients who require nutritional support during induction chemotherapy and/or radiation therapy. The jejunostomy tube is inserted 40 cm distal to the ligament of Treitz, using either a laparoscopic approach if technically feasible or through a small laparotomy incision. For patients who will likely resume oral intake early, it is reasonable to omit a jejunal feeding tube placement.
        </p>
        <p class="headingAnchor" id="H7393650">
         <span class="h1">
          POSTOPERATIVE MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Enteral feedings are started on postoperative day 2 and slowly advanced until feeding goals are attained at approximately postoperative day 5. A
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          barium
         </a>
         swallow is performed on postoperative day 7 to evaluate for leak and emptying of the conduit. The nasogastric tube generally remains in place until the barium swallow is performed and demonstrates no anastomotic leak. Patients are maintained on a minimal liquid diet for approximately two weeks to allow the conduit to remain decompressed and straight in the mediastinum. Early oral feeding may have some advantage without compromising outcome [
         <a href="#rid158">
          158
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15058.html" rel="external">
          "Complications of esophageal resection", section on 'Conduit complications'
         </a>
         .)
        </p>
        <p>
         Measures to reduce the risk of postoperative cardiovascular death, nonfatal myocardial infarction, and nonfatal cardiac arrest have included perioperative beta blockade, although the results of the Perioperative Ischemic Evaluation (POISE) trial [
         <a href="#rid159">
          159
         </a>
         ] have generated some measure of caution for this practice [
         <a href="#rid160">
          160
         </a>
         ]. In a randomized trial that included 8351 patients with or at high risk of atherosclerotic disease and scheduled for a noncardiac operation, patients receiving extended-release
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         succinate had a higher mortality rate compared with patients receiving a placebo (3.1 versus 2.3 percent, hazard ratio [HR] 1.33, 95% CI 1.03-1.74) [
         <a href="#rid159">
          159
         </a>
         ]. In addition, the risk of a cardiovascular accident (stroke) was also higher for the patients receiving metoprolol (1.0 versus 0.5 percent, HR 2.17, 95% CI 1.26-3.74). We prefer not to routinely use beta blockers for patients who have a minimally invasive esophagectomy, since their risk of atrial fibrillation is low.
        </p>
        <p>
         The guidelines for the perioperative management of patients with cardiac disease, including those of the American College of Cardiology/American Heart Association (ACC/AHA), are reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6615.html" rel="external">
          "Management of cardiac risk for noncardiac surgery"
         </a>
         .)
        </p>
        <p>
         The American College of Chest Physicians Guidelines on the Prevention of Venous Thromboembolism [
         <a href="#rid161">
          161,162
         </a>
         ] classify esophagectomy as a high-risk procedure and thus recommend postoperative thromboprophylaxis with low-molecular-weight heparin, unfractionated subcutaneous heparin three times daily, or
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          fondaparinux
         </a>
         . Conversely, some would classify esophagectomy as high risk for bleeding, especially in the setting of blunt mediastinal dissection, and thus argue for less aggressive prophylaxis. Further complicating the matter is the frequent use of neuraxial anesthesia, which further limits the use of perioperative anticoagulants for thromboprophylaxis [
         <a href="#rid163">
          163
         </a>
         ]. Unfortunately, a paucity of data exists to help clarify these issues, and, therefore, clinical practice varies. We use subcutaneous heparin and pneumatic boots beginning in the operating room and continuing until postoperative day 7 or until patients are ambulatory. For those with high risk of having a thromboembolic event, thromboprophylaxis may be extended to 30 days. (See
         <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">
          "Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H30348983">
         <span class="h1">
          MORBIDITY AND MORTALITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Morbidity and mortality rates vary, depending upon hospital and/or surgeon volume, patient comorbidities, and operative approach (eg, open, minimally invasive, tri-incisional) [
         <a href="#rid164">
          164-167
         </a>
         ]. Complications, mortality, and management of complications are discussed in a separate topic. (See
         <a class="medical medical_review" href="/z/d/html/15058.html" rel="external">
          "Complications of esophageal resection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7389764">
         <span class="h1">
          QUALITY OF LIFE
         </span>
         <span class="headingEndMark">
          —
         </span>
         An esophagectomy can exert temporary [
         <a href="#rid168">
          168-175
         </a>
         ] and long-term detrimental impacts on health-related quality of life (HR-QOL) [
         <a href="#rid172">
          172,174,176-178
         </a>
         ]. In most patients, recovery seems to occur within 12 to 24 months, but even after three or more years, a substantial number of long-term survivors still report residual problems with eating, breathlessness, diarrhea, reflux, fatigue, and odynophagia [
         <a href="#rid172">
          172,174,176,177
         </a>
         ]. In a self-reported quality-of-life study among 117 long-term-year survivors of esophageal cancer surgery, physical function was stable or improved at five years in 86 percent [
         <a href="#rid179">
          179
         </a>
         ].
        </p>
        <p>
         Recovery of HR-QOL may be related, at least in part, to the occurrence of postoperative complications. A prospective study that included 141 five-year survivors following an esophagectomy for cancer found that patients who sustained a major postoperative complication (eg, pneumonia, anastomotic leak; n = 46) had clinically and statistically significant more dyspnea compared with patients who did not have a major complication (mean score difference 15, 95% CI 6-23) [
         <a href="#rid178">
          178
         </a>
         ]. Patients with major postoperative complications also had significantly more fatigue and eating restrictions (mean score difference 13, 95% CI 5-20, and mean score difference 10, 95% CI 2-17, respectively).
        </p>
        <p class="headingAnchor" id="H3872936658">
         <span class="h1">
          SPECIAL CONSIDERATIONS DURING THE COVID-19 PANDEMIC
         </span>
         <span class="headingEndMark">
          —
         </span>
         The COVID-19 pandemic has increased the complexity of cancer care. Important issues include balancing the risk from delaying cancer treatment versus harm from COVID-19, minimizing the number of clinic and hospital visits to reduce exposure whenever possible, mitigating the negative impacts of social distancing on delivery of care, and appropriately and fairly allocating limited healthcare resources. Specific guidance for decision-making for cancer surgery on a disease-by-disease basis is available from the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.facs.org%252Fcovid-19%252Fclinical-guidance%252Felective-case%26data%3D02%7C01%7CCatherine.Zuo%2540wolterskluwer.com%7C6edf35fec8a44aa5ba7e08d7e0abd442%7C8ac76c91e7f141ffa89c3553b2da2c17%7C0%7C0%7C637224900908106614%26sdata%3DBZ46NEWlwLXBS%252BzuXX2ZECn0eWC5venMMOsQsbx20IU%253D%26reserved%3D0&amp;token=qRRbrus%2FSri1CCXBHEFm1Ig0Jf4oCI5jHTY3%2FI9L63gd4n8nQjiz8Ox53xBOxI8E%2FMGEWS15dXwsFTSZgwDwjK7tpJbBa7NEQzgTLxUtYffdRf%2F4Fc5rByj7%2FkXP%2FXUtHckhQ2Yn9GtqgHGuZSFWqdYkfvdALymVdcy2X3EZD5X5P%2BBfBtl2bm3Cf%2B9ww62XtFXXkI7Z6izXD1ShzwnO0bVvF0kxtVD9QvPzMPFBeink2fubU4mzobC1HeqSTv2vHII21kZGkZ7d%2FHiqD%2F2G1qh%2Frfk3P0SX8xOpV%2FlKqC21nZ0St6YyMu4GuKQ%2BaK4%2FDaOy5jcBYf48DUZwCH9s89Ivjs%2FHIWivzm2R9btOmkQ%3D&amp;TOPIC_ID=2530" target="_blank">
          American College of Surgeons
         </a>
         , from the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.surgonc.org%252Fresources%252Fcovid-19-resources%252F%26data%3D02%7C01%7CCatherine.Zuo%2540wolterskluwer.com%7C6edf35fec8a44aa5ba7e08d7e0abd442%7C8ac76c91e7f141ffa89c3553b2da2c17%7C0%7C0%7C637224900908116601%26sdata%3DpqQAjg%252F2hyLF5UboMZQ0FesSux0UjefT%252B6iDu1TycdY%253D%26reserved%3D0&amp;token=oOFUrQX%2Fyz9anNRKwsCcPypQbsLiACRwFTdqMBOyyCLjPjeuIcEQ1dPOVlN599%2BULH%2FuvVQKW7MZMVoWVWro8%2Fq5j7RI0ZnDY%2BOJjtqybxPVr%2B8Op54WnCF4LRSft%2F16SLu%2Fs2DKSJ5ElPtZYJWQyck25F8QCj%2F4MOUTABo%2BEEl7C8CexDrdaf99f%2FMjfSUcDcBq3KSDaxICfGfxQe5V%2Br61QeIpBSJRmQbFJT%2F8xgmGDzQoIXdLZ9FCfYfQMoYkq9%2BNp%2F0j%2F9nvjbTpQ6Js%2BnWyYDHtUNlN4o2EcvUT3jCXjP7i7YT8SsjaoGm5ZBMZSrf1V6wplIkswVdhZOS%2FwPgzEdu4rvZwnr6uNpk7Kkw%3D&amp;TOPIC_ID=2530" target="_blank">
          Society for Surgical Oncology
         </a>
         , and from others. These and other recommendations for cancer care during active phases of the COVID-19 pandemic are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/128993.html" rel="external">
          "COVID-19: Considerations in patients with cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1707668541">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/120117.html" rel="external">
          "Society guideline links: Esophageal cancer"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/122106.html" rel="external">
          "Society guideline links: Esophagectomy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H32960317">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The clinical spectrum of esophageal cancer has changed over the last few decades, with an increase in incidence of adenocarcinoma in the distal esophagus and a decrease in squamous cell carcinoma. However, patients with squamous cell carcinoma and adenocarcinoma are managed similarly from an operative point of view. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The selection criteria for eligibility for a surgical resection include localized T1 to T3 lesions and select T4a lesions that involve the pericardium, pleura, or diaphragm  (
         <a class="graphic graphic_table graphicRef111221" href="/z/d/graphic/111221.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Criteria for resection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Because most patients with a cervical esophageal cancer present with advanced disease, a surgical resection usually requires removal of portions of the pharynx, the larynx, the thyroid gland, and portions of the proximal esophagus. If there is sufficient margin on the upper esophageal sphincter, we perform a tri-incisional esophagectomy with a hand-sewn anastomosis to preserve esophageal length. (See
         <a class="local">
          'Cervical esophageal cancer resection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with a thoracic esophageal cancer, we perform a total thoracic esophagectomy with cervical esophagogastrostomy, radical two-field lymph node dissection, and jejunostomy feeding tube placement. (See
         <a class="local">
          'Thoracic cancer resection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We generally prefer a tri-incisional approach that consists of initial right posterolateral thoracotomy or thoracoscopic approach, followed by a laparotomy or via laparoscopy to obtain complete esophageal dissection and mobilization of the gastric conduit, en bloc resection of both mediastinal and upper abdominal lymph nodes, and a left neck incision and cervical anastomosis. (See
         <a class="local">
          'Tri-incisional esophagectomy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with an esophageal gastric junction cancer, we generally perform a total esophagectomy with cervical esophagogastrostomy with a partial gastrectomy or an extended gastrectomy, depending upon the extensiveness of the gastric involvement. An alternative to the total esophagectomy is the minimally invasive Ivor-Lewis procedure, with a thoracic esophagogastrostomy. However, there are insufficient data from randomized trials to determine the superiority of one approach over the other. (See
         <a class="local">
          'Esophagogastric junction cancer resection'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/15058.html" rel="external">
          "Complications of esophageal resection", section on 'Conduit complications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The integration of surgery into multimodality treatment of localized cancer of the esophagus is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2478.html" rel="external">
          "Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus"
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          SEER Stat Fact Sheets: Esophagus; Survival and Stage. seer.cancer.gov/statfacts/html/esoph.html#survival (Accessed on May 01, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Amico TA. Outcomes after surgery for esophageal cancer. Gastrointest Cancer Res 2007; 1:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirst J, Smithers BM, Gotley DC, et al. Defining cure for esophageal cancer: analysis of actual 5-year survivors following esophagectomy. Ann Surg Oncol 2011; 18:1766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyata H, Yamasaki M, Kurokawa Y, et al. Multimodal treatment for resectable esophageal cancer. Gen Thorac Cardiovasc Surg 2011; 59:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ajani J, D'Amico TA, Hayman JA, et al. Esophageal cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2003; 1:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999; 26:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roth JA. Treatment of esophageal cancer: does surgery make the cut? Gastrointest Cancer Res 2007; 1:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markar SR, Karthikesalingam A, Thrumurthy S, Low DE. Volume-outcome relationship in surgery for esophageal malignancy: systematic review and meta-analysis 2000-2011. J Gastrointest Surg 2012; 16:1055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNamara MJ, Adelstein DJ. Current developments in the management of locally advanced esophageal cancer. Curr Oncol Rep 2012; 14:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narsule CK, Montgomery MM, Fernando HC. Evidence-based review of the management of cancers of the gastroesophageal junction. Thorac Surg Clin 2012; 22:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83:2049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooke DT, Lau CL. Primary repair of esophageal perforation. Operative Techniques in Thoracic and Cardiovascular Surgery 2008; 13:126.
          </a>
         </li>
         <li class="breakAll">
          Rice TW, Kelsen D, Blackstone EH, et al. Esophagus and esophagogastric junction. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.185. Corrected at 4th printing, 2018.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu AJ, Goodman KA. Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet? J Gastrointest Oncol 2015; 6:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin SH, Wang J, Allen PK, et al. A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. J Gastrointest Oncol 2015; 6:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim JY, Correa AM, Vaporciyan AA, et al. Does the timing of esophagectomy after chemoradiation affect outcome? Ann Thorac Surg 2012; 93:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haisley KR, Laird AE, Nabavizadeh N, et al. Association of Intervals Between Neoadjuvant Chemoradiation and Surgical Resection With Pathologic Complete Response and Survival in Patients With Esophageal Cancer. JAMA Surg 2016; 151:e162743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumagai K, Rouvelas I, Tsai JA, et al. Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers. Br J Surg 2014; 101:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miao L, Chen H, Xiang J, Zhang Y. A high body mass index in esophageal cancer patients is not associated with adverse outcomes following esophagectomy. J Cancer Res Clin Oncol 2015; 141:941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minnella EM, Awasthi R, Loiselle SE, et al. Effect of Exercise and Nutrition Prehabilitation on Functional Capacity in Esophagogastric Cancer Surgery: A Randomized Clinical Trial. JAMA Surg 2018; 153:1081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Low DE, Allum W, De Manzoni G, et al. Guidelines for Perioperative Care in Esophagectomy: Enhanced Recovery After Surgery (ERAS®) Society Recommendations. World J Surg 2019; 43:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inoue J, Ono R, Makiura D, et al. Prevention of postoperative pulmonary complications through intensive preoperative respiratory rehabilitation in patients with esophageal cancer. Dis Esophagus 2013; 26:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Affleck DG, Karwande SV, Bull DA, et al. Functional outcome and survival after pharyngolaryngoesophagectomy for cancer. Am J Surg 2000; 180:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Triboulet JP, Mariette C, Chevalier D, Amrouni H. Surgical management of carcinoma of the hypopharynx and cervical esophagus: analysis of 209 cases. Arch Surg 2001; 136:1164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang HW, Chu PY, Kuo KT, et al. A reappraisal of surgical management for squamous cell carcinoma in the pharyngoesophageal junction. J Surg Oncol 2006; 93:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peracchia A, Bonavina L, Botturi M, et al. Current status of surgery for carcinoma of the hypopharynx and cervical esophagus. Dis Esophagus 2001; 14:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saito R, Suzuki H, Motoyama S, et al. A clinical study of surgical treatment of patients with carcinoma of the cervical esophagus extending to the thoracic esophagus. Jpn J Thorac Cardiovasc Surg 2000; 48:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amatsu M, Mohri M, Kinishi M. Significance of retropharyngeal node dissection at radical surgery for carcinoma of the hypopharynx and cervical esophagus. Laryngoscope 2001; 111:1099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelley DJ, Wolf R, Shaha AR, et al. Impact of clinicopathologic parameters on patient survival in carcinoma of the cervical esophagus. Am J Surg 1995; 170:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daiko H, Hayashi R, Saikawa M, et al. Surgical management of carcinoma of the cervical esophagus. J Surg Oncol 2007; 96:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ott K, Lordick F, Molls M, et al. Limited resection and free jejunal graft interposition for squamous cell carcinoma of the cervical oesophagus. Br J Surg 2009; 96:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayanagi S, Onitsuka T, Nakagawa M, et al. The use of short segment free jejunal transfer as salvage surgery for cervical esophageal and hypopharyngeal cancer. World J Surg 2014; 38:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pesko P, Sabljak P, Bjelovic M, et al. Surgical treatment and clinical course of patients with hypopharyngeal carcinoma. Dis Esophagus 2006; 19:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hosch SB, Stoecklein NH, Pichlmeier U, et al. Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance. J Clin Oncol 2001; 19:1970.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nigro JJ, Hagen JA, DeMeester TR, et al. Prevalence and location of nodal metastases in distal esophageal adenocarcinoma confined to the wall: implications for therapy. J Thorac Cardiovasc Surg 1999; 117:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kato H, Tachimori Y, Watanabe H, et al. Intramural metastasis of thoracic esophageal carcinoma. Int J Cancer 1992; 50:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein HJ, Hutter J, Feith M, von Rahden BH. Limited surgical resection and jejunal interposition for early adenocarcinoma of the distal esophagus. Semin Thorac Cardiovasc Surg 2007; 19:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korst RJ, Altorki NK. Extent of resection and lymphadenectomy in early Barrett's cancer. Dis Esophagus 1997; 10:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collard JM, Romagnoli R, Hermans BP, Malaise J. Radical esophageal resection for adenocarcinoma arising in Barrett's esophagus. Am J Surg 1997; 174:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Igaki H, Kato H, Tachimori Y, et al. Prognostic evaluation for squamous cell carcinomas of the lower thoracic esophagus treated with three-field lymph node dissection. Eur J Cardiothorac Surg 2001; 19:887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujita H, Kakegawa T, Yamana H, et al. Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy. Ann Surg 1995; 222:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osugi H, Takemura M, Takada N, et al. Prognostic factors after oesophagectomy and extended lymphadenectomy for squamous oesophageal cancer. Br J Surg 2002; 89:909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watanabe H, Kato H, Tachimori Y. Significance of extended systemic lymph node dissection for thoracic esophageal carcinoma in Japan. Recent Results Cancer Res 2000; 155:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tachibana M, Kinugasa S, Yoshimura H, et al. Clinical outcomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma. Am J Surg 2005; 189:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shim YM, Kim HK, Kim K. Comparison of survival and recurrence pattern between two-field and three-field lymph node dissections for upper thoracic esophageal squamous cell carcinoma. J Thorac Oncol 2010; 5:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu PK, Wang BY, Chou TY, et al. The total number of resected lymph node is not a prognostic factor for recurrence in esophageal squamous cell carcinoma patients undergone transthoracic esophagectomy. J Surg Oncol 2011; 103:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cense HA, Visser MR, van Sandick JW, et al. Quality of life after colon interposition by necessity for esophageal cancer replacement. J Surg Oncol 2004; 88:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mansour KA, Bryan FC, Carlson GW. Bowel interposition for esophageal replacement: twenty-five-year experience. Ann Thorac Surg 1997; 64:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis PA, Law S, Wong J. Colonic interposition after esophagectomy for cancer. Arch Surg 2003; 138:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeMeester SR. Colon interposition following esophagectomy. Dis Esophagus 2001; 14:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swisher SG, Hofstetter WL, Miller MJ. The supercharged microvascular jejunal interposition. Semin Thorac Cardiovasc Surg 2007; 19:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rao YG, Pal S, Pande GK, et al. Transhiatal esophagectomy for benign and malignant conditions. Am J Surg 2002; 184:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellis FH Jr, Gibb SP, Watkins E Jr. Esophagogastrectomy. A safe, widely applicable, and expeditious form of palliation for patients with carcinoma of the esophagus and cardia. Ann Surg 1983; 198:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orringer MB, Marshall B, Chang AC, et al. Two thousand transhiatal esophagectomies: changing trends, lessons learned. Ann Surg 2007; 246:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orringer MB, Marshall B, Iannettoni MD. Transhiatal esophagectomy: clinical experience and refinements. Ann Surg 1999; 230:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macha M, Whyte RI. The current role of transhiatal esophagectomy. Chest Surg Clin N Am 2000; 10:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Sandick JW, van Lanschot JJ, ten Kate FJ, et al. Indicators of prognosis after transhiatal esophageal resection without thoracotomy for cancer. J Am Coll Surg 2002; 194:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paç M, Başoglu A, Koçak H, et al. Transhiatal versus transthoracic esophagectomy for esophageal cancer. J Thorac Cardiovasc Surg 1993; 106:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang AC, Ji H, Birkmeyer NJ, et al. Outcomes after transhiatal and transthoracic esophagectomy for cancer. Ann Thorac Surg 2008; 85:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baba M, Aikou T, Natsugoe S, et al. Appraisal of ten-year survival following esophagectomy for carcinoma of the esophagus with emphasis on quality of life. World J Surg 1997; 21:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urschel JD. Esophagogastrostomy anastomotic leaks complicating esophagectomy: a review. Am J Surg 1995; 169:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller JM, Erasmi H, Stelzner M, et al. Surgical therapy of oesophageal carcinoma. Br J Surg 1990; 77:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patil PK, Patel SG, Mistry RC, et al. Cancer of the esophagus: esophagogastric anastomotic leak--a retrospective study of predisposing factors. J Surg Oncol 1992; 49:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agrawal S, Deshmukh SP, Patil PK, et al. Intrathoracic anastomosis after oesophageal resection for cancer. J Surg Oncol 1996; 63:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whooley BP, Law S, Alexandrou A, et al. Critical appraisal of the significance of intrathoracic anastomotic leakage after esophagectomy for cancer. Am J Surg 2001; 181:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffin SM, Lamb PJ, Dresner SM, et al. Diagnosis and management of a mediastinal leak following radical oesophagectomy. Br J Surg 2001; 88:1346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Price TN, Nichols FC, Harmsen WS, et al. A comprehensive review of anastomotic technique in 432 esophagectomies. Ann Thorac Surg 2013; 95:1154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathisen DJ, Grillo HC, Wilkins EW Jr, et al. Transthoracic esophagectomy: a safe approach to carcinoma of the esophagus. Ann Thorac Surg 1988; 45:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellis FH Jr, Heatley GJ, Krasna MJ, et al. Esophagogastrectomy for carcinoma of the esophagus and cardia: a comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria. J Thorac Cardiovasc Surg 1997; 113:836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akiyama H, Tsurumaru M, Watanabe G, et al. Development of surgery for carcinoma of the esophagus. Am J Surg 1984; 147:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turnbull AD, Ginsberg RJ. Options in the surgical treatment of esophageal carcinoma. Chest Surg Clin N Am 1994; 4:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Visbal AL, Allen MS, Miller DL, et al. Ivor Lewis esophagogastrectomy for esophageal cancer. Ann Thorac Surg 2001; 71:1803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffin SM, Shaw IH, Dresner SM. Early complications after Ivor Lewis subtotal esophagectomy with two-field lymphadenectomy: risk factors and management. J Am Coll Surg 2002; 194:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyle MJ, Franceschi D, Livingstone AS. Transhiatal versus transthoracic esophagectomy: complication and survival rates. Am Surg 1999; 65:1137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stark SP, Romberg MS, Pierce GE, et al. Transhiatal versus transthoracic esophagectomy for adenocarcinoma of the distal esophagus and cardia. Am J Surg 1996; 172:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chu KM, Law SY, Fok M, Wong J. A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma. Am J Surg 1997; 174:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007; 246:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldminc M, Maddern G, Le Prise E, et al. Oesophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial. Br J Surg 1993; 80:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rentz J, Bull D, Harpole D, et al. Transthoracic versus transhiatal esophagectomy: a prospective study of 945 patients. J Thorac Cardiovasc Surg 2003; 125:1114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hulscher JB, Tijssen JG, Obertop H, van Lanschot JJ. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg 2001; 72:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krasna MJ. Left transthoracic esophagectomy. Chest Surg Clin N Am 1995; 5:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swanson SJ, Batirel HF, Bueno R, et al. Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Ann Thorac Surg 2001; 72:1918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swanson SJ, Sugarbaker DJ. The three-hole esophagectomy. The Brigham and Women's Hospital approach (modified McKeown technique). Chest Surg Clin N Am 2000; 10:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKeown KC. Total three-stage oesophagectomy for cancer of the oesophagus. Br J Surg 1976; 63:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKeown KC. The surgical treatment of carcinoma of the oesophagus. A review of the results in 478 cases. J R Coll Surg Edinb 1985; 30:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finley FJ, Lamy A, Clifton J, et al. Gastrointestinal function following esophagectomy for malignancy. Am J Surg 1995; 169:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vigneswaran WT, Trastek VF, Pairolero PC, et al. Transhiatal esophagectomy for carcinoma of the esophagus. Ann Thorac Surg 1993; 56:838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ito H, Clancy TE, Osteen RT, et al. Adenocarcinoma of the gastric cardia: what is the optimal surgical approach? J Am Coll Surg 2004; 199:880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbour AP, Rizk NP, Gonen M, et al. Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg 2007; 246:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002; 347:1662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sasako M, Sano T, Yamamoto S, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 2006; 7:644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiesser M, Schneider PM. Surgical strategies for adenocarcinoma of the esophagogastric junction. Recent Results Cancer Res 2010; 182:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurokawa Y, Sasako M, Sano T, et al. Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia. Br J Surg 2015; 102:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santillan AA, Farma JM, Meredith KL, et al. Minimally invasive surgery for esophageal cancer. J Natl Compr Canc Netw 2008; 6:879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamoto S, Kawahara K, Maekawa T, et al. Minimally invasive esophagectomy for stage I and II esophageal cancer. Ann Thorac Surg 2005; 80:2070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osugi H, Takemura M, Higashino M, et al. A comparison of video-assisted thoracoscopic oesophagectomy and radical lymph node dissection for squamous cell cancer of the oesophagus with open operation. Br J Surg 2003; 90:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berrisford RG, Wajed SA, Sanders D, Rucklidge MW. Short-term outcomes following total minimally invasive oesophagectomy. Br J Surg 2008; 95:602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roig-García J, Gironés-Vilà J, Garsot-Savall E, et al. [Transthoracic and transhiatal esophagectomy using minimally invasive techniques. Experience in 50 patients]. Cir Esp 2008; 83:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagpal K, Ahmed K, Vats A, et al. Is minimally invasive surgery beneficial in the management of esophageal cancer? A meta-analysis. Surg Endosc 2010; 24:1621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dantoc M, Cox MR, Eslick GD. Evidence to support the use of minimally invasive esophagectomy for esophageal cancer: a meta-analysis. Arch Surg 2012; 147:768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mamidanna R, Bottle A, Aylin P, et al. Short-term outcomes following open versus minimally invasive esophagectomy for cancer in England: a population-based national study. Ann Surg 2012; 255:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gottlieb-Vedi E, Kauppila JH, Malietzis G, et al. Long-term Survival in Esophageal Cancer After Minimally Invasive Compared to Open Esophagectomy: A Systematic Review and Meta-analysis. Ann Surg 2019; 270:1005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinoza-Mercado F, Imai TA, Borgella JD, et al. Does the Approach Matter? Comparing Survival in Robotic, Minimally Invasive, and Open Esophagectomies. Ann Thorac Surg 2019; 107:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dapri G, Himpens J, Cadière GB. Minimally invasive esophagectomy for cancer: laparoscopic transhiatal procedure or thoracoscopy in prone position followed by laparoscopy? Surg Endosc 2008; 22:1060.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galvani CA, Gorodner MV, Moser F, et al. Robotically assisted laparoscopic transhiatal esophagectomy. Surg Endosc 2008; 22:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braghetto I, Csendes A, Cardemil G, et al. Open transthoracic or transhiatal esophagectomy versus minimally invasive esophagectomy in terms of morbidity, mortality and survival. Surg Endosc 2006; 20:1681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avital S, Zundel N, Szomstein S, Rosenthal R. Laparoscopic transhiatal esophagectomy for esophageal cancer. Am J Surg 2005; 190:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luketich JD, Alvelo-Rivera M, Buenaventura PO, et al. Minimally invasive esophagectomy: outcomes in 222 patients. Ann Surg 2003; 238:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh RK, Pham TH, Diggs BS, et al. Minimally invasive esophagectomy provides equivalent oncologic outcomes to open esophagectomy for locally advanced (stage II or III) esophageal carcinoma. Arch Surg 2011; 146:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luketich JD, Pennathur A, Awais O, et al. Outcomes after minimally invasive esophagectomy: review of over 1000 patients. Ann Surg 2012; 256:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biere SS, van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet 2012; 379:1887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Straatman J, van der Wielen N, Cuesta MA, et al. Minimally Invasive Versus Open Esophageal Resection: Three-year Follow-up of the Previously Reported Randomized Controlled Trial: the TIME Trial. Ann Surg 2017; 266:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Sluis PC, van der Horst S, May AM, et al. Robot-assisted Minimally Invasive Thoracolaparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy for Resectable Esophageal Cancer: A Randomized Controlled Trial. Ann Surg 2019; 269:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Y, Han Y, Gan Q, et al. Early Outcomes of Robot-Assisted Versus Thoracoscopic-Assisted Ivor Lewis Esophagectomy for Esophageal Cancer: A Propensity Score-Matched Study. Ann Surg Oncol 2019; 26:1284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smithers BM, Gotley DC, Martin I, Thomas JM. Comparison of the outcomes between open and minimally invasive esophagectomy. Ann Surg 2007; 245:232.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN Guidelines). Esophageal and esophagogastric junction cancers. Available at: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf (Accessed on February 07, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Workum F, Fransen L, Luyer MD, Rosman C. Learning curves in minimally invasive esophagectomy. World J Gastroenterol 2018; 24:4974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White A, Kucukak S, Lee DN, et al. Ivor Lewis minimally invasive esophagectomy for esophageal cancer: An excellent operation that improves with experience. J Thorac Cardiovasc Surg 2019; 157:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Law S, Fok M, Chu KM, Wong J. Thoracoscopic esophagectomy for esophageal cancer. Surgery 1997; 122:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akaishi T, Kaneda I, Higuchi N, et al. Thoracoscopic en bloc total esophagectomy with radical mediastinal lymphadenectomy. J Thorac Cardiovasc Surg 1996; 112:1533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smithers BM, Gotley DC, McEwan D, et al. Thoracoscopic mobilization of the esophagus. A 6 year experience. Surg Endosc 2001; 15:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mariette C, Markar SR, Dabakuyo-Yonli TS, et al. Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer. N Engl J Med 2019; 380:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gurusamy KS, Pallari E, Midya S, Mughal M. Laparoscopic versus open transhiatal oesophagectomy for oesophageal cancer. Cochrane Database Syst Rev 2016; 3:CD011390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan DS, Reid TD, Howell I, Lewis WG. Systematic review and meta-analysis of the influence of circumferential resection margin involvement on survival in patients with operable oesophageal cancer. Br J Surg 2013; 100:456.
          </a>
         </li>
         <li class="breakAll">
          College of American Pathologists. Surgical Pathology Cancer Case Summary (Checklist): Esophagus. College of American Pathologists: Northfield, 2005.
         </li>
         <li class="breakAll">
          Mapstone N. Minimum Dataset for Oeophageal Carcinoma Histopathology Reports (1st ed). Royal College of Pathologists: London, 1998.
         </li>
         <li class="breakAll">
          Mapstone N. Dataset for the Histopathological Reporting of Oesophageal Carcinoma (2nd ed). Royal College of Pathologists: London, 2006.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenstein AJ, Litle VR, Swanson SJ, et al. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer 2008; 112:1239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable esophageal cancer. J Gastrointest Surg 2007; 11:1384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peyre CG, Hagen JA, DeMeester SR, et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg 2008; 248:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizk NP, Ishwaran H, Rice TW, et al. Optimum lymphadenectomy for esophageal cancer. Ann Surg 2010; 251:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guo X, Wang Z, Yang H, et al. Impact of Lymph Node Dissection on Survival After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: From the Results of NEOCRTEC5010, a Randomized Multicenter Study. Ann Surg 2023; 277:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li B, Chen H, Xiang J, et al. Pattern of lymphatic spread in thoracic esophageal squamous cell carcinoma: A single-institution experience. J Thorac Cardiovasc Surg 2012; 144:778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg 2002; 236:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hulscher JB, Van Sandick JW, Offerhaus GJ, et al. Prospective analysis of the diagnostic yield of extended en bloc resection for adenocarcinoma of the oesophagus or gastric cardia. Br J Surg 2001; 88:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dresner SM, Griffin SM. Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. Br J Surg 2000; 87:1426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujita H, Sueyoshi S, Tanaka T, et al. Optimal lymphadenectomy for squamous cell carcinoma in the thoracic esophagus: comparing the short- and long-term outcome among the four types of lymphadenectomy. World J Surg 2003; 27:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishihira T, Hirayama K, Mori S. A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg 1998; 175:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saluja SS, Ray S, Pal S, et al. Randomized trial comparing side-to-side stapled and hand-sewn esophagogastric anastomosis in neck. J Gastrointest Surg 2012; 16:1287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim RH, Takabe K. Methods of esophagogastric anastomoses following esophagectomy for cancer: A systematic review. J Surg Oncol 2010; 101:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biere SS, Maas KW, Cuesta MA, van der Peet DL. Cervical or thoracic anastomosis after esophagectomy for cancer: a systematic review and meta-analysis. Dig Surg 2011; 28:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Law S, Fok M, Chu KM, Wong J. Comparison of hand-sewn and stapled esophagogastric anastomosis after esophageal resection for cancer: a prospective randomized controlled trial. Ann Surg 1997; 226:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu HH, Chen JS, Huang PM, et al. Comparison of manual and mechanical cervical esophagogastric anastomosis after esophageal resection for squamous cell carcinoma: a prospective randomized controlled trial. Eur J Cardiothorac Surg 2004; 25:1097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beitler AL, Urschel JD. Comparison of stapled and hand-sewn esophagogastric anastomoses. Am J Surg 1998; 175:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collard JM, Romagnoli R, Goncette L, et al. Terminalized semimechanical side-to-side suture technique for cervical esophagogastrostomy. Ann Thorac Surg 1998; 65:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orringer MB, Marshall B, Iannettoni MD. Eliminating the cervical esophagogastric anastomotic leak with a side-to-side stapled anastomosis. J Thorac Cardiovasc Surg 2000; 119:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ercan S, Rice TW, Murthy SC, et al. Does esophagogastric anastomotic technique influence the outcome of patients with esophageal cancer? J Thorac Cardiovasc Surg 2005; 129:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Honda M, Kuriyama A, Noma H, et al. Hand-sewn versus mechanical esophagogastric anastomosis after esophagectomy: a systematic review and meta-analysis. Ann Surg 2013; 257:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walther B, Johansson J, Johnsson F, et al. Cervical or thoracic anastomosis after esophageal resection and gastric tube reconstruction: a prospective randomized trial comparing sutured neck anastomosis with stapled intrathoracic anastomosis. Ann Surg 2003; 238:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gooszen JAH, Goense L, Gisbertz SS, et al. Intrathoracic versus cervical anastomosis and predictors of anastomotic leakage after oesophagectomy for cancer. Br J Surg 2018; 105:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urschel JD, Urschel DM, Miller JD, et al. A meta-analysis of randomized controlled trials of route of reconstruction after esophagectomy for cancer. Am J Surg 2001; 182:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collard JM, Tinton N, Malaise J, et al. Esophageal replacement: gastric tube or whole stomach? Ann Thorac Surg 1995; 60:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ngan SY, Wong J. Lengths of different routes for esophageal replacement. J Thorac Cardiovasc Surg 1986; 91:790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanuti M, de Delva PE, Wright CD, et al. Post-esophagectomy gastric outlet obstruction: role of pyloromyotomy and management with endoscopic pyloric dilatation. Eur J Cardiothorac Surg 2007; 31:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urschel JD, Blewett CJ, Young JE, et al. Pyloric drainage (pyloroplasty) or no drainage in gastric reconstruction after esophagectomy: a meta-analysis of randomized controlled trials. Dig Surg 2002; 19:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atkins BZ, Shah AS, Hutcheson KA, et al. Reducing hospital morbidity and mortality following esophagectomy. Ann Thorac Surg 2004; 78:1170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gockel I, Kneist W, Keilmann A, Junginger T. Recurrent laryngeal nerve paralysis (RLNP) following esophagectomy for carcinoma. Eur J Surg Oncol 2005; 31:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun HB, Li Y, Liu XB, et al. Early Oral Feeding Following McKeown Minimally Invasive Esophagectomy: An Open-label, Randomized, Controlled, Noninferiority Trial. Ann Surg 2018; 267:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           POISE Study Group, Devereaux PJ, Yang H, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008; 371:1839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devereaux PJ, Guyatt G, Yang H, et al. Essay for the CIHR/CMAJ award: impact of the Perioperative Ischemic Evaluation (POISE) trial. CMAJ 2011; 183:E351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:381S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e227S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horlocker TT, Vandermeuelen E, Kopp SL, et al. Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition). Reg Anesth Pain Med 2018; 43:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metzger R, Bollschweiler E, Vallböhmer D, et al. High volume centers for esophagectomy: what is the number needed to achieve low postoperative mortality? Dis Esophagus 2004; 17:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bailey SH, Bull DA, Harpole DH, et al. Outcomes after esophagectomy: a ten-year prospective cohort. Ann Thorac Surg 2003; 75:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seely AJ, Ivanovic J, Threader J, et al. Systematic classification of morbidity and mortality after thoracic surgery. Ann Thorac Surg 2010; 90:936.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shen KR, Harrison-Phipps KM, Cassivi SD, et al. Esophagectomy after anti-reflux surgery. J Thorac Cardiovasc Surg 2010; 139:969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blazeby JM, Sanford E, Falk SJ, et al. Health-related quality of life during neoadjuvant treatment and surgery for localized esophageal carcinoma. Cancer 2005; 103:1791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blazeby JM, Farndon JR, Donovan J, Alderson D. A prospective longitudinal study examining the quality of life of patients with esophageal carcinoma. Cancer 2000; 88:1781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Boer AG, van Lanschot JJ, van Sandick JW, et al. Quality of life after transhiatal compared with extended transthoracic resection for adenocarcinoma of the esophagus. J Clin Oncol 2004; 22:4202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynolds JV, McLaughlin R, Moore J, et al. Prospective evaluation of quality of life in patients with localized oesophageal cancer treated by multimodality therapy or surgery alone. Br J Surg 2006; 93:1084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viklund P, Wengström Y, Rouvelas I, et al. Quality of life and persisting symptoms after oesophageal cancer surgery. Eur J Cancer 2006; 42:1407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parameswaran R, McNair A, Avery KN, et al. The role of health-related quality of life outcomes in clinical decision making in surgery for esophageal cancer: a systematic review. Ann Surg Oncol 2008; 15:2372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Djärv T, Lagergren J, Blazeby JM, Lagergren P. Long-term health-related quality of life following surgery for oesophageal cancer. Br J Surg 2008; 95:1121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Djärv T, Blazeby JM, Lagergren P. Predictors of postoperative quality of life after esophagectomy for cancer. J Clin Oncol 2009; 27:1963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gockel I, Gönner U, Domeyer M, et al. Long-term survivors of esophageal cancer: disease-specific quality of life, general health and complications. J Surg Oncol 2010; 102:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hurmuzlu M, Aarstad HJ, Aarstad AK, et al. Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer. Dis Esophagus 2011; 24:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Derogar M, Orsini N, Sadr-Azodi O, Lagergren P. Influence of major postoperative complications on health-related quality of life among long-term survivors of esophageal cancer surgery. J Clin Oncol 2012; 30:1615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Derogar M, Lagergren P. Health-related quality of life among 5-year survivors of esophageal cancer surgery: a prospective population-based study. J Clin Oncol 2012; 30:413.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2530 Version 48.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : SEER Stat Fact Sheets: Esophagus; Survival and Stage. seer.cancer.gov/statfacts/html/esoph.html#survival (Accessed on May 01, 2012).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19262708" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Outcomes after surgery for esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21213056" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Defining cure for esophageal cancer: analysis of actual 5-year survivors following esophagectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21751104" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Multimodal treatment for resectable esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19764147" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Esophageal cancer. Clinical practice guidelines in oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10566604" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The changing epidemiology of esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19262711" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Treatment of esophageal cancer: does surgery make the cut?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22089950" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Volume-outcome relationship in surgery for esophageal malignancy: systematic review and meta-analysis 2000-2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22544559" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Current developments in the management of locally advanced esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22108695" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Evidence-based review of the management of cancers of the gastroesophageal junction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9827707" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Changing patterns in the incidence of esophageal and gastric carcinoma in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Primary repair of esophageal perforation
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Primary repair of esophageal perforation
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25642338" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25642337" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21962263" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Does the timing of esophagectomy after chemoradiation affect outcome?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27627765" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Association of Intervals Between Neoadjuvant Chemoradiation and Surgical Resection With Pathologic Complete Response and Survival in Patients With Esophageal Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24493117" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25428458" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : A high body mass index in esophageal cancer patients is not associated with adverse outcomes following esophagectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30193337" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Effect of Exercise and Nutrition Prehabilitation on Functional Capacity in Esophagogastric Cancer Surgery: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30276441" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Guidelines for Perioperative Care in Esophagectomy: Enhanced Recovery After Surgery (ERAS®) Society Recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22409435" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Prevention of postoperative pulmonary complications through intensive preoperative respiratory rehabilitation in patients with esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11182415" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Functional outcome and survival after pharyngolaryngoesophagectomy for cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11585510" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Surgical management of carcinoma of the hypopharynx and cervical esophagus: analysis of 209 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16615159" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : A reappraisal of surgical management for squamous cell carcinoma in the pharyngoesophageal junction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11553216" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Current status of surgery for carcinoma of the hypopharynx and cervical esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10965613" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : A clinical study of surgical treatment of patients with carcinoma of the cervical esophagus extending to the thoracic esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11404628" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Significance of retropharyngeal node dissection at radical surgery for carcinoma of the hypopharynx and cervical esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7485725" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Impact of clinicopathologic parameters on patient survival in carcinoma of the cervical esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17443746" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Surgical management of carcinoma of the cervical esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19224522" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Limited resection and free jejunal graft interposition for squamous cell carcinoma of the cervical oesophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24081534" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The use of short segment free jejunal transfer as salvage surgery for cervical esophageal and hypopharyngeal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16866855" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Surgical treatment and clinical course of patients with hypopharyngeal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11283129" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9869753" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Prevalence and location of nodal metastases in distal esophageal adenocarcinoma confined to the wall: implications for therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1728612" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Intramural metastasis of thoracic esophageal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17403461" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Limited surgical resection and jejunal interposition for early adenocarcinoma of the distal esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9280075" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Extent of resection and lymphadenectomy in early Barrett's cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9324143" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Radical esophageal resection for adenocarcinoma arising in Barrett's esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11404147" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Prognostic evaluation for squamous cell carcinomas of the lower thoracic esophagus treated with three-field lymph node dissection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7487213" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12081742" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Prognostic factors after oesophagectomy and extended lymphadenectomy for squamous oesophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10693246" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Significance of extended systemic lymph node dissection for thoracic esophageal carcinoma in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15701501" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Clinical outcomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20421764" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Comparison of survival and recurrence pattern between two-field and three-field lymph node dissections for upper thoracic esophageal squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21400526" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The total number of resected lymph node is not a prognostic factor for recurrence in esophageal squamous cell carcinoma patients undergone transthoracic esophagectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15384087" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Quality of life after colon interposition by necessity for esophageal cancer replacement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9307469" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Bowel interposition for esophageal replacement: twenty-five-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12611579" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Colonic interposition after esophagectomy for cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11869314" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Colon interposition following esophagectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17403459" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The supercharged microvascular jejunal interposition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12169357" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Transhiatal esophagectomy for benign and malignant conditions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6194763" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Esophagogastrectomy. A safe, widely applicable, and expeditious form of palliation for patients with carcinoma of the esophagus and cardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17717440" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Two thousand transhiatal esophagectomies: changing trends, lessons learned.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10493486" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Transhiatal esophagectomy: clinical experience and refinements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10967753" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The current role of transhiatal esophagectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11803954" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Indicators of prognosis after transhiatal esophageal resection without thoracotomy for cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8341062" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Transhiatal versus transthoracic esophagectomy for esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18222237" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Outcomes after transhiatal and transthoracic esophagectomy for cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9015171" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Appraisal of ten-year survival following esophagectomy for carcinoma of the esophagus with emphasis on quality of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7771633" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Esophagogastrostomy anastomotic leaks complicating esophagectomy: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2203505" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Surgical therapy of oesophageal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1548890" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Cancer of the esophagus: esophagogastric anastomotic leak--a retrospective study of predisposing factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8841467" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Intrathoracic anastomosis after oesophageal resection for cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11376570" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Critical appraisal of the significance of intrathoracic anastomotic leakage after esophagectomy for cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11578290" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Diagnosis and management of a mediastinal leak following radical oesophagectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23395626" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : A comprehensive review of anastomotic technique in 432 esophagectomies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3277551" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Transthoracic esophagectomy: a safe approach to carcinoma of the esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9159617" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Esophagogastrectomy for carcinoma of the esophagus and cardia: a comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6691556" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Development of surgery for carcinoma of the esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8049999" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Options in the surgical treatment of esophageal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11426751" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Ivor Lewis esophagogastrectomy for esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11893132" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Early complications after Ivor Lewis subtotal esophagectomy with two-field lymphadenectomy: risk factors and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10597061" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Transhiatal versus transthoracic esophagectomy: complication and survival rates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8942548" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Transhiatal versus transthoracic esophagectomy for adenocarcinoma of the distal esophagus and cardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9324146" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18043101" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8472154" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Oesophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12771885" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Transthoracic versus transhiatal esophagectomy: a prospective study of 945 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11465217" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7583038" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Left transthoracic esophagectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11789772" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10967755" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The three-hole esophagectomy. The Brigham and Women's Hospital approach (modified McKeown technique).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1276657" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Total three-stage oesophagectomy for cancer of the oesophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3989754" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : The surgical treatment of carcinoma of the oesophagus. A review of the results in 478 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7747821" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Gastrointestinal function following esophagectomy for malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8215660" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Transhiatal esophagectomy for carcinoma of the esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15555971" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Adenocarcinoma of the gastric cardia: what is the optimal surgical approach?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17592282" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12444180" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16887481" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20676874" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Surgical strategies for adenocarcinoma of the esophagogastric junction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25605628" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18926097" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Minimally invasive surgery for esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16305846" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Minimally invasive esophagectomy for stage I and II esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12520585" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : A comparison of video-assisted thoracoscopic oesophagectomy and radical lymph node dissection for squamous cell cancer of the oesophagus with open operation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18324607" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Short-term outcomes following total minimally invasive oesophagectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18358177" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : [Transthoracic and transhiatal esophagectomy using minimally invasive techniques. Experience in 50 patients].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20108155" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Is minimally invasive surgery beneficial in the management of esophageal cancer? A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22911078" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Evidence to support the use of minimally invasive esophagectomy for esophageal cancer: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22173202" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Short-term outcomes following open versus minimally invasive esophagectomy for cancer in England: a population-based national study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30817355" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Long-term Survival in Esophageal Cancer After Minimally Invasive Compared to Open Esophagectomy: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30312615" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Does the Approach Matter? Comparing Survival in Robotic, Minimally Invasive, and Open Esophagectomies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18071806" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Minimally invasive esophagectomy for cancer: laparoscopic transhiatal procedure or thoracoscopy in prone position followed by laparoscopy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17939004" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Robotically assisted laparoscopic transhiatal esophagectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16960662" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Open transthoracic or transhiatal esophagectomy versus minimally invasive esophagectomy in terms of morbidity, mortality and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15972176" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Laparoscopic transhiatal esophagectomy for esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14530720" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Minimally invasive esophagectomy: outcomes in 222 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21690448" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Minimally invasive esophagectomy provides equivalent oncologic outcomes to open esophagectomy for locally advanced (stage II or III) esophageal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22668811" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Outcomes after minimally invasive esophagectomy: review of over 1000 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22552194" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28187044" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Minimally Invasive Versus Open Esophageal Resection: Three-year Follow-up of the Previously Reported Randomized Controlled Trial: the TIME Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30308612" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Robot-assisted Minimally Invasive Thoracolaparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy for Resectable Esophageal Cancer: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30843161" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Early Outcomes of Robot-Assisted Versus Thoracoscopic-Assisted Ivor Lewis Esophagectomy for Esophageal Cancer: A Propensity Score-Matched Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17245176" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Comparison of the outcomes between open and minimally invasive esophagectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17245176" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Comparison of the outcomes between open and minimally invasive esophagectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30510372" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Learning curves in minimally invasive esophagectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30459111" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Ivor Lewis minimally invasive esophagectomy for esophageal cancer: An excellent operation that improves with experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9225908" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Thoracoscopic esophagectomy for esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8975845" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Thoracoscopic en bloc total esophagectomy with radical mediastinal lymphadenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11285963" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Thoracoscopic mobilization of the esophagus. A 6 year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30625052" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27030301" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Laparoscopic versus open transhiatal oesophagectomy for oesophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23319427" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Systematic review and meta-analysis of the influence of circumferential resection margin involvement on survival in patients with operable oesophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23319427" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Systematic review and meta-analysis of the influence of circumferential resection margin involvement on survival in patients with operable oesophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23319427" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Systematic review and meta-analysis of the influence of circumferential resection margin involvement on survival in patients with operable oesophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23319427" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Systematic review and meta-analysis of the influence of circumferential resection margin involvement on survival in patients with operable oesophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18224663" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17764019" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Clinical impact of lymphadenectomy extent in resectable esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18936567" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20032718" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Optimum lymphadenectomy for esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33605586" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Impact of Lymph Node Dissection on Survival After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22889480" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Pattern of lymphatic spread in thoracic esophageal squamous cell carcinoma: A single-institution experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12170022" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11350447" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Prospective analysis of the diagnostic yield of extended en bloc resection for adenocarcinoma of the oesophagus or gastric cardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11044172" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12715226" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Optimal lymphadenectomy for squamous cell carcinoma in the thoracic esophagus: comparing the short- and long-term outcome among the four types of lymphadenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9445239" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22528571" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Randomized trial comparing side-to-side stapled and hand-sewn esophagogastric anastomosis in neck.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20401920" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Methods of esophagogastric anastomoses following esophagectomy for cancer: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21293129" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Cervical or thoracic anastomosis after esophagectomy for cancer: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9296510" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Comparison of hand-sewn and stapled esophagogastric anastomosis after esophageal resection for cancer: a prospective randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15145015" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Comparison of manual and mechanical cervical esophagogastric anastomosis after esophageal resection for squamous cell carcinoma: a prospective randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9568667" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Comparison of stapled and hand-sewn esophagogastric anastomoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9527220" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Terminalized semimechanical side-to-side suture technique for cervical esophagogastrostomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10649203" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Eliminating the cervical esophagogastric anastomotic leak with a side-to-side stapled anastomosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15746747" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Does esophagogastric anastomotic technique influence the outcome of patients with esophageal cancer?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23001084" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Hand-sewn versus mechanical esophagogastric anastomosis after esophagectomy: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14631217" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Cervical or thoracic anastomosis after esophageal resection and gastric tube reconstruction: a prospective randomized trial comparing sutured neck anastomosis with stapled intrathoracic anastomosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29412450" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Intrathoracic versus cervical anastomosis and predictors of anastomotic leakage after oesophagectomy for cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11754853" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : A meta-analysis of randomized controlled trials of route of reconstruction after esophagectomy for cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7646084" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Esophageal replacement: gastric tube or whole stomach?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3702486" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Lengths of different routes for esophageal replacement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17166733" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Post-esophagectomy gastric outlet obstruction: role of pyloromyotomy and management with endoscopic pyloric dilatation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12119515" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Pyloric drainage (pyloroplasty) or no drainage in gastric reconstruction after esophagectomy: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15464465" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Reducing hospital morbidity and mortality following esophagectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15780563" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Recurrent laryngeal nerve paralysis (RLNP) following esophagectomy for carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28549015" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Early Oral Feeding Following McKeown Minimally Invasive Esophagectomy: An Open-label, Randomized, Controlled, Noninferiority Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18479744" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21422131" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Essay for the CIHR/CMAJ award: impact of the Perioperative Ischemic Evaluation (POISE) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18574271" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22315263" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29561531" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15569369" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : High volume centers for esophagectomy: what is the number needed to achieve low postoperative mortality?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12537219" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Outcomes after esophagectomy: a ten-year prospective cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20732521" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Systematic classification of morbidity and mortality after thoracic surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20304141" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Esophagectomy after anti-reflux surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15779022" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Health-related quality of life during neoadjuvant treatment and surgery for localized esophageal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10760752" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : A prospective longitudinal study examining the quality of life of patients with esophageal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15483031" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : Quality of life after transhiatal compared with extended transthoracic resection for adenocarcinoma of the esophagus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16779881" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Prospective evaluation of quality of life in patients with localized oesophageal cancer treated by multimodality therapy or surgery alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16737812" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Quality of life and persisting symptoms after oesophageal cancer surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18626719" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : The role of health-related quality of life outcomes in clinical decision making in surgery for esophageal cancer: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18581441" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Long-term health-related quality of life following surgery for oesophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19289614" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Predictors of postoperative quality of life after esophagectomy for cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19877161" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : Long-term survivors of esophageal cancer: disease-specific quality of life, general health and complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20819100" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22473157" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : Influence of major postoperative complications on health-related quality of life among long-term survivors of esophageal cancer surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22215745" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : Health-related quality of life among 5-year survivors of esophageal cancer surgery: a prospective population-based study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
